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ABSTRACT OF DISSERTATION

INTEGRIN α5β1 AS A NOVEL TARGET WITH THE SMALL PEPTIDE,
ATN-161, IN THE TREATMENT OF ISCHEMIC STROKE
Stroke is the 5th leading cause of death and the leading cause of disability
in the United States, but there are only two available therapies, tissue plasminogen
activator and endovascular thrombectomy. As both therapies focus on removal of
the clot, the subsequent pathologic processes, i.e. inflammation, cerebrovascular
breakdown, ATP depletion, etc. are left untreated, contributing to worsened patient
outcome. Many clinical trials have unsuccessfully attempted to address these
mechanisms. The blood-brain barrier (BBB), a system of non-fenestrated
endothelial cells, extracellular matrix, and astrocytic endfeet, is significantly
impacted after ischemic stroke in its role of preventing the free movement of
proteins from the blood into the brain. In fact, BBB dysfunction is viewed as one of
the major facilitators of damage following ischemic stroke, leading to increased
infarct volumes and worsened patient outcomes. Interestingly, a family of
endothelial integrins, the b1 integrins, have been shown to regulate tight junction
proteins preventing the free movement of molecules. When expression of the tight
junctions are decreased, this results in increased BBB permeability. To test this
concept, our laboratory has previously shown the knockout of the particular b1
integrin, a5b1, is neuroprotective following ischemic stroke through BBB
stabilization.
To determine if therapeutically targeting integrin α5β1 was feasible, we first
determined if brain integrin a5b1 expression increases after experimental mouse
ischemic stroke model, specifically tandem/transient common carotid artery/middle
cerebral artery occlusion. We found that integrin α5β1 does increase acutely, by
post-stroke day (PSD)2, and continued in an exponential fashion through PSD4.
Next, we determined if integrin α5β1 was therapeutically accessible by systemic
treatment (i.e. intraperitoneal or intravenous) by being located on the inside
(luminal surface) of vasculature. We found that location of integrin a5b1 was
dependent on the area relative to the stroke injury. The core, or area of direct
impact, demonstrated expression of integrin α5β1 on the outside vasculature
(abluminal surface), while per-infarct expression was localized to the lumen. Lastly,
to determine the activity of integrin α5β1 following ischemic stroke, we showed that

the potential ligands (binding partners), plasma fibronectin, fibrinogen, and
amyloid-b, do not bind integrin α5β1 after ischemic stroke.
Next, we determined the therapeutic potential of targeting integrin α5β1 with
the small peptide, ATN-161. ATN-161 has undergone clinical trials in solid tumors,
with limited side effects reported. First, we determined that intraperitoneal (IP)
injection of ATN-161 was safe after ischemic stroke, showing no changes in heart
rate, pulse distention (blood pressure), or body temperature. Next, we found that
IP administration of ATN-161 after experimental ischemic stroke reduced infarct
volumes, edema, and functional deficit. Furthermore, these results were due to
reduction of BBB permeability and anti-inflammatory effects. Interestingly, ATN161 reduced cytokine production, prevented leukocyte infiltration, and leukocyte
recruitment. Collectively, these results suggest that targeting integrin α5β1 with
ATN-161 is 1) feasible, 2) safe and 3) effective, suggesting that ATN-161 may be
a novel therapeutic treatment for ischemic stroke.
Keywords: Ischemic Stroke, Integrin a5b1, Therapeutic targeting, Blood-brain
barrier, Inflammation
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Chapter 1: Roles of blood-brain barrier integrins and extracellular matrix in
stroke
Danielle Edwards, and Gregory J. Bix

Introduction
Stroke is the fifth most common cause of death in the United States (separate from
cardiovascular disease), with a person experiencing a stroke every 40 seconds (1).
The most common type of stroke, ischemic stroke, is defined as obstruction of
blood flow to part of the brain due to a thrombus or blood clot, and results in a one
year patient survival rate of 60% (1-4). While all are potentially at risk for having a
stroke, factors such as being male (or a post-menopausal female), AfricanAmerican, being of advanced age, and the presence of hypertension all increase
a person’s risk of experiencing a stroke in their lifetime (5-11). Additionally,
functional deficits induced by ischemic stroke are the leading cause of disability in
the US and cause a $36-65 billion economic burden that is expected to increase
to $180 billion by 2030 (8). Taken together, ischemic stroke is a significant health
issue with limited therapeutic options. The current therapies, exogenously
administered clot-busting tissue plasminogen activator (t-PA) and endovascular
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mechanical thrombectomy (clot removal), are efficient in removing the thrombus,
thereby increasing reperfusion rates by 60%, and decreasing mortality (since
2013) (3-4). However, increased efficacy (i.e. morbidity) due to therapeutic input
have largely lagged behind these gains in mortality (12-13).

A proposed hypothesis to explain the lack of correlation between improved
mortality rates and patient outcomes involves the mechanisms following
reperfusion, so-called reperfusion induced injury. When reperfusion injury occurs,
it often expands the initial brain injury caused by the occlusion (referred to as the
core) to at risk brain tissue (referred to as the penumbra or peri-infarct region (1416). This occurs, in part, as the result of cerebral edema (brain swelling). The first
phase of edema occurring at 0-24 hours post-injury is cytotoxic (ionic and
metabolic dysfunction (16)) in nature, followed by vasogenic edema attributed to
angiogenesis (new blood vessel growth) and reassembly of endothelial cell tight
junctions (16-18).

Edema greatly contributes to breakdown of the blood-brain barrier (BBB), a threelayer defense system around the cerebral vasculature, preventing unwanted
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molecules from entering the brain parenchyma. The BBB is comprised of nonfenestrated endothelial cells with intercellular tight junctions and various influx and
efflux cellular transporters, extracellular matrix (ECM) and its cellular integrin
receptors, pericytes, and astrocytic endfeet (Figure 1.1) (16). BBB dysfunction in
transient ischemic stroke models, in which a cerebral blood vessel is closed for a
predetermined period of time and then reopened, occurs in two phases (biphasic
permeabilization); at 30 minutes post-reopening of the blood vessel, and then
again at 2-5 days post occlusion, lasting for up to 5 weeks (19-22). The loss of
organization leading to BBB dysfunction can be observed by the loss of sharp
distinction in the basement membrane 12-24 hours after ischemia, as shown by
transmission electron microscopy (23). The importance of BBB dysfunction has
come under high scrutiny over recent years, as studies have shown that BBB
dysfunction can predict the probability of having an ischemic stroke as well as its
outcome (24-28). This review focuses on the modulation of integrins and ECM
components (existing in and around all cell types in the cerebrum) following
reperfusion, and how this can lead to BBB dysfunction following ischemic stroke
(Figure 1.2).

3

Figure 1.1: Representation of the blood-brain barrier during normal conditions.
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Figure 1.2: Representation of integrin and extracellular matrix effects of the cerebral
neurovascular unit A. during maturity and B. following reperfusion after ischemic stroke.
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Proteins of the Blood-Brain Barrier
Integrins
Integrins as a whole are located on every cell type in the body. They are
heterodimeric transmembrane proteins composed of non-covalently bound α and
β subunits forming 24 known combinations (29). The different subunits have
varying roles; the α subunit is responsible for intracellular signaling (30-32).
Integrins exist in three states- active, at rest, and inactive, represented by different
conformations (16,33). The conformational states differentially expose the binding
domain, typically Arginine-Glycine-Aspartate (the three-amino acid sequence,
RGD) and determine the relative (none, intermediate, or high) affinity an integrin
will have for ECM components (16,34). Once bound to their corresponding ECM
protein, the integrin-ECM complex functions to promote cellular signaling,
proliferation, migration, differentiation, and survival (35-38). We will first discuss
several key integrins that have been implicated in BBB function after stroke, and,
where known, their respective therapeutic target potential. Here, we will discuss
integrins associated with the extracellular matrix, though blood borne integrins
(α2β1 and α11bβ3) are also effected following ischemic stroke.
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Integrin αvβ3
Embryonically, integrin αvβ3 is highly expressed on endothelial cells, astrocytes,
and microglia, binding to a number of ECM components including fibronectin,
vitronectin, osteopontin, laminin, etc. (39-42). Functionally, αvβ3 is essential to
angiogenesis, as 80% of αv knockout mice are embryonic lethal by E10-12 with
placental and heart defects, though this is not completely attributed to the β3
subunit as αv can also associate with β3, β5, β6, and β8 subunits with varying
viability (43). The remaining 20% of mutants survive through gestation, but end up
succumbing to intestinal and cerebral hemorrhages at birth (43). Interestingly,
conditional αv knockout mice also result in non-survivability due to intracerebral
hemorrhages, but not by loss of integrin αv on endothelial cells. Instead, integrin
αv absence on glial cells and astrocytes facilitates detachment of astrocytes from
the ECM, an increase in permeability of the BBB, and intracerebral hemorrhage
(44). Completion of development results in total loss of αvβ3 expression under
physiologic conditions (41).

After experimental ischemic stroke (middle cerebral artery occlusion (MCAO)) in
adult rodents, expression of integrin αvβ3 is significantly increased by 2 hours in
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the ischemic core and continues to increase in the ischemic penumbra until
expression peaks at 7 days post stroke (45-46). This correlates with increases in
the ECM proteins fibronectin and vitronectin as well as increasing vascular density
(as determined through brain endothelial proliferation) through post stroke day 14
in the ischemic penumbra (45-46). Furthermore, vascular endothelial growth factor
(VEGF) (47), a known inducer of integrin αvβ3 expression, activity, and ligand
affinity, has a similar pattern of upregulation after MCAO, increasing around 1 hour
post-reperfusion and remaining for up to 7 days (45,48). The increase in αvβ3 poststroke induces occludin and zona occludins (ZO-1) (tight junctions of brain
endothelial cells) internalization, disrupts VE-cadherin localization (a tight junction
regulating protein), induces stress fiber formation, and increases expression of
ECM degradation proteins, matrix metalloproteinase (MMP) -2 and -9 (27,41,4954). These outcomes initiate angiogenesis, a process that was previously thought
to be beneficial by increasing blood supply to a previously hypoperfused area, but
is now known as a main contributor to the chronic (2-5 day) increase in BBB
permeability after reperfusion (16). As αvβ3 is a known promoter of the chronic
(2-5 days) increase in permeability observed after reperfusion, it may be a good
target for ischemic stroke intervention (16).
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Over the last few years, different modes of targeting integrin αvβ3 therapeutically
have been attempted with contrasting results. The first and most promising
combined a 1 hour pre-MCAO and 3 hours post-MCAO therapeutic treatment with
an integrin αvβ3 selective inhibitor, cyclo-RGDfV, which showed reduced infarct
volumes and BBB permeability (55). However, prophylactic treatment for ischemic
stroke is not a viable clinical option as we cannot predict the moment a stroke will
occur. Because of this, the same group attempted to inhibit αvβ3 3 hours postMCAO. A decrease in BBB permeability was still observed, but the resulting
decrease in infarct volume was not significant in this dosing paradigm (56).
Additional results with the cyclo-RGDfV inhibitor demonstrated a decrease in
phosphorylated Flk-1, a specific vascular endothelial growth factor (VEGF)
receptor, that when phosphorylated, increases VEGFa production, consistent in
both dosing windows (55-56). This suggest that the decreases in BBB permeability
are due to changes in VEGF- αvβ3 mediated angiogenesis, but inhibition of this
mechanism alone in insufficient to modulate infarct volumes. This may be due to
inhibitor dosing schedule (first dose is too late or repetitive dosing is necessary) or
that additional mechanisms are required for effects on infarct volume.
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Integrin α5β1
Integrin α5β1’s main function is to promote embryonic angiogenesis, but it has also
been implicated in cell migration, cell adhesion, and cell survival (57). It is also
present on many different cell types, most notably on endothelial cells and
astrocytes in the cerebrum, with a preference for interacting with the ECM proteins
fibronectin, laminin 10, and osteopontin (57). Even with its diverse binding
preferences, integrin α5β1 is primarily known as a fibronectin receptor (57).
Interestingly, recent research has shown that integrin αvβ3 competitively binds to
fibronectin, creating cross-talk signals that recruit integrin α5β1 at an opposite,
unspecified site on fibronectin (58). Ultimately, these interactions increase the
adhesion of both integrins αvβ3 and α5β1 to fibronectin (58). Unlike with integrin
αvβ3’s non-detectable expression in adult microvasculature, after embryogenesis,
integrin α5β1’s expression decreases but is still present at low levels in adult
vasculature (41,46,57). The relevance of integrin’s α5β1 in development is
apparent, as multiple α5 knockout mice models do not survive past E11 due to
neural tube defects, lack of angiogenesis, and leaky blood vessels (43,59-61).
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α5β1 may play a key role in many different diseases. Notably, targeting α5β1 in
cancer has been highly studied as it is significantly upregulated in tumorgenesis,
with functions in tumor development, angiogenesis, and progression (57). This
increase is not limited to cancer, but is observed in models of experimental
ischemic stroke, increasing in the ischemic penumbra around day 4 until peak
expression at 7 days post-stroke, the same pattern of expression as αvβ3 integrin
and brain endothelial cell proliferation (46). Unlike with αvβ3, there is a
compensatory increase in integrin α5β1 when integrin αvβ3 is inhibited (62).
Furthermore, α5β1 is closely linked to VEGF receptor-1 (VEGFR-1) (as seen by a
solid-phase binding assay), and upon cross-talk, enhances cell migration,
proliferation, and adhesion, processes which are blocked upon use of integrin α5antibodies and knockout mice (63-64). Because of its strong angiogenic ties,
integrin α5β1 has been highly targeted as a means for therapeutic intervention in
inhibiting angiogenesis for many decades with varying results (refer to ref 9 for
further information), but its role in angiogenesis and stroke pathology has been
largely ignored until recently.
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Roberts et al studied the effects of integrin α5β1 in endothelial specific knockout
mice after MCAO with surprising results (65). These mice, unlike the previously
discussed pan knockouts, are not embryonically lethal and have no obvious
vascular or developmental changes (65-66). Surprisingly, these knockout mice
suffered significantly smaller infarcts compared to their wild type controls through
apparent stabilization of the BBB as shown by an absence of IgG (150 kDa)
extravasation into the brain parenchyma (65). This is suited toward the hypothesis
that inhibition of angiogenesis, in this case through inhibition of integrin α5β1,
prevents a remodeling of neurovasculature initiated by vasogenic edema. As
embryonic pan-deletion of integrin α5 contributes to abnormal angiogenesis and
leaky blood vessels (59-61), inhibition of integrin α5β1 therapeutically in already
developed, adult vasculature could be an avenue for future ischemic stroke
intervention.

Integrin α6β4
Integrin α6β4 is mainly expressed on astrocytes, but also on endothelial cells,
though it is not expressed during embryogenesis, but rather during adult
vasculogenesis due to the switch from fibronectin- to laminin-driven angiogenesis
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(66-68). Initially, α6β4 decreases within 2-4 hours after MCAO, but begins to
increase at day 4 and continues to peak expression by day 14 (66-69). Increased
α6β4 expression also correlates to increasing brain endothelial cell proliferation
(reaching its peak at day 7), which swaps with astrocytic proliferation that peaks at
day 14 (46,64). The astrocytic effects after ischemic stroke will be discussed later
in this review.

Integrin α6β1
As with most β1 integrins, α6β1 integrin is expressed on endothelial cells in the
brain (39). During embryogenesis, the endothelial integrins α5β1 and αvβ3 are the
most highly expressed, but an integrin switch occurs for the laminin binding α6β1
integrin in adulthood (67). α6β1 continues to be the dominantly expressed β1
integrin in mature vessels, but this is quickly switched for α5β1 after cerebral
hypoxia, once angiogenesis is initiated (62). Current research on therapeutically
targeting this integrin has focused on blocking it to prevent angiogenesis in solid
tumors with very limited study in ischemic stroke.
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Integrin α1β1
α1β1 integrin is present on endothelial cells and astrocytes, preferably binding to
the ECM components collagen IV and perlecan. Embryonically, α1 integrin subunit
knockout mice show no lethality and finite defects, limited to cell proliferation
complications (43). On the contrary, β1 integrin subunit knockout mice, eliminating
all the various integrins with a β1 component, show neonatal lethality at E6 while
embryonic stem cells without β1 integrin result in hematopoietic defects (43). After
experimental ischemic stroke, α1β1 expression (by probing α1 and β1 separately)
decreases by 30% within 2 hours, and 75% by 24 hours after occlusion (69).
Further studies with integrin β1 inhibitory antibodies have resulted in severe
deficiencies in BBB stability as well as promoting a decrease in expression of the
tight junction protein claudin-5 and shifting its localization away from the
extracellular wall, suggesting a significant role in BBB maintenance embryonically
and at maturity (70), though no further research has been conducted in this regard
in ischemic stroke.
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Integrins: Conclusion
As described here, the variety of integrins in the brain is expansive in terms of type,
function / preferred ligand(s), and expression. The highly reactive nature of
integrins suggests a new approach for potential ischemic stroke therapy, as
evidenced by a relatively recent increase in the number of studies focused on them.
However, the success of modulating these integrins to therapeutic effect is thus
far as varied as is the integrins themselves.

Extracellular Matrix Proteins
Collectively, the ECM consists of multimeric proteins that participate in cellular
migration and differentiation as well as functioning as a support system for
endothelial cells and astrocytes when in complex with integrins, and is composed
of a combination of proteoglycans, glycoproteins, and collagens (71-72). The ECM
is vital for development, function, and regulation of vasculature, tight junctions,
neurons, and astrocytes through cellular signaling and adhesion (73). Defects in
any ECM protein can result in serious developmental and functional complications
(73). Here, we will discuss the cerebrovascular extracellular matrix proteins that
interact with integrins following ischemic stroke.
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Fibronectin
The ECM glycoprotein fibronectin is a disulfide-linked dimer (~250 kDa per
monomer) that can exist as a soluble form, plasma fibronectin produced by
hepatocytes in the liver, or insoluble form, cellular fibronectin produced by
fibroblasts in the basement membrane (66,74-76). Developmentally, fibronectin is
significantly increased in the basement membrane, driving angiogenesis in
developing vasculature through binding to integrins α5β1 and αvβ3 (77-78).
Fibronectin knockout mice are embryonic lethal at E10 due to severe vascular,
notochord, and somite deformities, due to genetic manipulation to the fibronectin
gene before isoform formation due to splicing can occur (59). This is evident as
the cellular fibronectin isoform is necessary for cerebral vascular development, but
these vasculature and notochord deformities, in addition to preventing lethality
from the null gene, are prevented in the plasma fibronectin null mouse (66,79-80).

Fibronectin is highly reactive after stroke, increasing in the ischemic penumbra
until peak expression at 7 days post MCAO, but the researchers did not separate
expression by isoform (46,81). Previous studies suggest that the increase is due
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to trafficked plasma fibronectin to the infarct area 2 days post MCAO (79). To
further reinforce this concept, plasma fibronectin null mice that underwent MCAO
had significantly increased infarct volumes and increased TUNEL (apoptotic cells)
staining compared to their wild-type controls with no compensation from cellular
fibronectin (79,82).

Not only is fibronectin responsive after stroke, but it is also vulnerable to
degradation from proteases, most notably MMPs (83-84). MMP-9 is increased by
48 hours after ischemic stroke in humans (85), but also after intracerebral
hemorrhage induced by VEGF injections and IL-1β induced systemic inflammation
by nearly 6-fold (86-87), increasing the degradation of ECM proteins. With this
relationship in mind, serum levels of cellular fibronectin and MMP-9 are increased
in patients who experience a hemorrhagic transformation following ischemic stroke
(88-89). Interestingly, the higher levels of both cellular fibronectin and MMP-9
predict increased bleeding associated with the hemorrhage.
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Laminin
Laminin is a heterotrimeric protein composed of different α, β, and γ subunits to
form 15 different isoforms (90-93) that exists in endothelial cells and astrocytes.
While embryonic angiogenesis is driven by fibronectin, this is substituted by
laminin during adult angiogenesis (67,94), though this process will continually
alternate during VEGF stimulated injury (i.e. tumor growth and metastasis,
ischemia, wound healing, etc.) (31,46,67,81). Of the 5 α, 4 β, and 3 γ laminin
subunits, laminin 8 (α4β1γ1) and 10 (α5β1γ1) are endothelial specific, while
laminin 1 (α1β1γ1) and 2 (α2β1γ1) are expressed solely on astrocytes (95-98). It
is important to note that only laminin 8 is expressed during development, while the
first detectable levels of laminin 10 are 3-4 weeks post-birth in mice (91,99). The
importance of laminin to vascular integrity is obvious as laminin α4 knockout mice
and laminin γ1 knockout mice suffer from leaky vasculature and experience
intracerebral hemorrhages, leading to lethality at E6 (99-100). Further study with
conditional laminin α4 knockout mice show similar defects in vasculature that again
lead to intracerebral hemorrhages (101-102).
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Laminin’s main role after ischemic stroke appears to be more aligned with its
endothelial cell interactions. Within 24 hours after MCAO, increases in laminin in
both endothelial cells (laminin 8 and 10) and astrocytes (laminin 1 and 2) in the
ischemic penumbra are observed (95,103). Alternatively, there is a decrease in
endothelial laminin located in the ischemic core due to loss of vasculature from
ischemic conditions (81). Endothelial laminin, specifically laminin 10, is also
essential for BBB integrity after in vitro oxygen glucose deprivation by regulating
occludin and ZO-1 expression and localization to the extracellular cell wall,
decreasing paracellular resistance through the endothelial cells (104). Finally,
activation of integrin α2β1 by its binding to endothelial laminin halts endothelial
proliferation (105), a process that is slowed around 7 days post MCAO (59) when
astrocytic proliferation takes over (46,67).

Chronic repair has been implicated in laminin-initiated mechanisms driving
neurogenesis after MCAO. Endothelial laminin promotes neurite growth in vitro
(106), but has yet to be detected in in vivo studies. Recent studies have shown
laminin in conjunction with β1 integrin in providing scaffolds, a neural chain that
promotes neuronal migration toward injury, 16 days after occlusion (107). Although

20

laminin-mediated neurogenesis after MCAO is poorly understood, the impact that
this glycoprotein has on neurogenesis could be significant.

Perlecan
Perlecan is a heparan sulfate proteoglycan that contains a protein core with 5
different domains (domain I-V) and three glycosaminoglycan chains at the Nterminus and is most commonly found in hyaline cartilage, but is also located in
basement membranes throughout the body (108-110). Overall, perlecan plays a
major role in cellular migration, proliferation, and differentiation, but the individual
domains have functions and binding domains unique to their sequence and
structure (6,110). Perlecan, like fibronectin and laminin, is upregulated during
embryogenesis around cerebral vasculature to provide maintenance and
assemble the developing basement membranes (47,111). When absent from the
basement membrane, complete perlecan knockout mice result in embryonic
lethality at E12 resulting from cardiac failure and exencephaly, with surviving
embryos soon succumbing to their skeletal, cardiac, and cerebral defects
(47,111,112). On the other hand, a second type of transgenic mouse with
truncated perlecan (producing 10% of total perlecan, perlecan hypomorphs) yield
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surviving neonates that have a normal basement membrane, but are still
susceptible to exencephaly as well as exhibit truncated skeletal features (47,113).
Collectively, the loss of perlecan embryonically and in maturation display
significance in both transgenic mouse models show high importance in basement
membrane maintenance in both development and adulthood, and though perlecan
is mostly known for its functions in hyaline cartilage, it has shown interesting
promise as a target for ischemic stroke therapy (108,93).

Perlecan is decreased by 43-63% within 2 hours of reperfusion after MCAO and is
continually degraded through day 7 by cathepsin (caspase) B and L (62,114).
Cleavage by cathepsin L on perlecan releases the C-terminal fragment domain v
within hours after experimental ischemic stroke, resulting in a strong increase by
24 hours post-reperfusion that is sustained through 7 days (115). Treatment with
exogenous recombinant domain V after MCAO not only is neuroprotective in wildtype mice, but rescues pathology in perlecan deficient mice (i.e. perlecan
hypomorphs), thus reducing infarct volumes and improving functional outcomes
(neuroprotection and neurorepair) (114-116). Furthermore, the neuroprotective
effects of domain V were blocked upon administration of an anti-α5β1 antibody.
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Interestingly, integrin α5β1 is a potential receptor of domain V, but not perlecan
(115). Collectively, these results suggest that perlecan, and its domain V in
particular, play a fundamental role in the brain’s response to ischemic stroke injury.

Collagen IV
Collagens are an abundant basal lamina protein expressed on all tissue types in
the body (117). Of the variety of collagens, the most abundant in the basement
membrane in the body is collagen IV, a nonfibrillary collagen (117). Even though
collagen IV is one of the three main components of the basement membrane
(laminin and heparan sulfate proteoglycans composing the rest), embryonically
knocked out collagen IV result in no cerebral deficits, but rather only appearing to
affect renal development (43,117). Interestingly, mature mutations can result in
ischemic strokes in young patients, potentially resulting in a significant role in poststroke pathology (118). Studies in collagen IV expression have been contradictory.
One study using western blot analysis shows a reduction in collagen IV after
experimental ischemic stroke that corresponds to a decrease in cerebral
vasculature (119). Although, more recent studies have observed the opposite
phenomenon when analyzing by immunohistochemistry (120). Here, the authors
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themselves admit the potential false-positive in the results because of a potential
increase in degradation (i.e. more proteins available for targeting) or as a result of
the neurovasculature over compensating to stabilize damaged vessels (120).
These conflicting results need more investigation and improvement before any
determination of collagen IV’s impact on stroke severity or post-stroke recovery
can be made.

Extracellular Matrix Proteins: Conclusion
The proteins in the extracellular matrix surrounding endothelial cells and astrocytes
are primarily composed of collagen IV, laminin, heparan sulfate proteoglycans, and
fibronectin. This diverse group has a variety of reactions following stroke, but
overall are attributed to the BBB stability, an important target to reduce the
expansion of damage and edema. The interest in targeting these proteins has
been limited at best, most likely due to a decrease in accessibility on the basal side
of the endothelium. Current focus is on modulating these proteins through other
mechanisms, such as reducing MMPs, targeting integrins, and understanding the
full reactive mechanisms after ischemic stroke.
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Cellular Components of the BBB
As discussed, integrins and ECM proteins are not limited to endothelial cells, but
span all cell types in the neurovascular unit including astrocytes and pericytes.
When ischemia and the following inflammatory, vasogenic, etc. mechanisms
influence these BBB components, it can directly affect BBB permeability (16).
Below, we briefly describe the rest of the cells that comprise the BBB with a
particular focus on how their interactions with the ECM via integrins affect the BBB
after ischemic stroke.

Endothelial Cells
Endothelial cells are responsible for the first layer of the BBB, providing a scaffold
for TJ, junctional adhesion molecules (JAM), and the extracellular matrix (as
discussed throughout this review). Heavy scrutiny has been placed on paracellular
permeability, permeability between endothelial cells, as the main regulator for poststroke edema (121). Until recently, little importance has been placed on
transcellular permeability, permeability through an endothelial cell. It has now been
shown that endothelial cells undergo a 4-step process after ischemic stroke,
localized to the core (122). First, endothelial cells swell, potentially attributed to

25

activation of connexin-43, a gap junction protein (121), Next, endothelial cells gain
a permeable surface. Here, an increase in transcytotic, particularly caveolin-1, and
pincytotic vesicles begin to compromise the endothelial cells and cause an
increase in BBB permeability at 4-6 hours (121-124). Interestingly, at this time,
there appears to be limited compromise of the tight junctions. This process leads
to free movement of molecules across the endothelial cell, eventually resulting in
a loss of endothelial integrity (121). Finally, this is followed by a loss of endothelial
integrity, Once the extracellular matrix is exposed, endothelial cell loss occurs
(124). The endothelial role in BBB permeability is shown to be resolved 24 hours
post-stroke (122). Because of this process, the early damage done to endothelial
cells following ischemic stroke could be a potential therapeutic target of acute
treatment.

Astrocytes
Astrocytes, particularly their extended endfeet surrounding the ECM and pericytes,
are the last line of defense to prevent unwanted proteins, molecules, etc. (125).
The endfeet are also stabilizers of the BBB by releasing paracrine signaling (as
determined by neurons), but can modulate cerebral blood flow, neuronal functions,
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and tight junction formations as well (126-130). Astrocytic dysfunction, as seen by
the separation of astrocytic endfeet with the basement membrane, occurs early
after MCAO, within 2 hours (53,59). This process is referred to as astrocytic
swelling and corresponds to increases in BBB permeability by way of cytotoxic
edema, the loss of two astrocytic-endothelial cell anchoring proteins, α1β1 and
α6β1 integrins, and an increase in excretion of MMPs (69,86-87). Overall, this
acute mechanism after ischemia is responsible for cellular death of astrocytes,
exacerbating cytotoxic edema and BBB dysfunction and thus the damage after
ischemic stroke (69,82,131).

Interestingly, expression of the astrocytic-associated integrins has been the focus
of post-stroke research, but little attention has been placed on their potential as a
therapeutic target (see above). A possible explanation for this may be due to the
loss of astrocytes inducing demyelination in the white matter that is absent in grey
matter (132). Previous research has described a higher contact between the
astrocytes and endothelium in the white matter (101). Because rodents possess
significantly less white matter than humans, this increases the difficulty and
potential lack of translation of any therapy targeting astrocytic associated integrins.
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Pericytes
Pericytes exist between astrocytes and the ECM to form a support system
(scaffold) for endothelial cells as well as to send paracrine signals by direct contact
to the endothelium (133-134). Additionally, pericytes are essential for regulation of
ECM proteins, particularly astrocytic laminins 1 and 2 (135). After ischemia,
pericyte detachment occurs within 2 hours post reperfusion, inducing
hypoperfusion. Increases in post-stroke VEGF levels facilitate the detachment of
pericytes from the endothelium, promoting an increase in MMP-9 expression
(increasing ECM degradation) and caveolae-mediated transyctosis (increased
BBB permeability) in both in vivo and in vitro models (5,136-141). Furthermore,
these pericytic induced increases in BBB permeability is region specific, occurring
more prominently in the cortex, striatum and hippocampus (142). Administration of
a VEGF inhibitor in vitro reversed the BBB permeability effects (136). Pericytes are
also composed of actin and myosin filaments, generating smooth muscle type
actions (116,144). Contraction of the pericytes, decreasing the diameter of
capillary vessels, is due to the acute ATP depletion following ischemic reperfusion,
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resulting in a reduced or complete lack of cerebral blood flow even after removal
of a thrombus (“no-reflow” phenomenon) (98,145-147).

Future Considerations
Integrins, ECM constituents, and the rest of the components of the BBB are
significantly impacted after ischemic stroke. From the influence of integrin-ECM
complexes, growth factors, TJ remodeling, MMPs, etc. there are many different
targets that one could turn their attention to for potential breakthroughs in
understanding stroke pathophysiology and developing new therapies, although
some may have more promise than others (Figure 1.3).

The importance of these components, particularly integrins and ECM proteins, in
embryonic development convey their fundamental necessity for cerebral
vasculature development and maintenance as demonstrated by embryonic
lethality of nearly every knockout. Because of this, genetic changes (mutations,
deletions, etc.) may influence the probability of experiencing a stroke and/or a
stroke’s severity, whether from BBB dysfunction or clot formation (i.e. α2β1). For
example, recent investigation has found that a polymorphism in the α2 subunit at
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Figure 1.3: Proposed future applications for integrins and extracellular matrix in ischemic
stroke.
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C807T increases the probability of stroke by 1.266 times (148). This discovery is
limited to clot formation, most likely due to increases in cholesterol in these patients
(148), but the significance of potential genetic alterations should not be
understated.

As discussed, it is proposed that vasogenic edema after ischemic stroke is driven
by angiogenesis (16-18) and the reorganization of BBB that must occur during this
process. Angiogenesis after ischemic stroke is separated into three stages,
initiation, migration and stabilization of new vasculature, and maturation (149-150).
Previous studies that have focused on increasing angiogenesis after ischemic
stroke based on the fact that patients with increased cerebrovasculature
experience better outcomes, have had limited success (151-152). Instead, our
focus may need to turn toward inhibiting pro-angiogenic integrins (α5β1 and αvβ3)
and ECM proteins (fibronectin) to prevent early angiogenesis.

This appears

counterintuitive; why prevent the growth of new blood vessels to an area that has
experienced significant loss of cerebral blood flow and damaged vasculature in the
ischemic core? As discussed in this review, mechanisms following ischemic stroke
not only increase pro-angiogenic proteins, but also growth factors (VEGF) that in
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turn facilitate the release of pericytes from vasculature, and MMPs, increasing BBB
breakdown. Furthermore, the novel finding that α5 endothelial specific knockout
mice have smaller infarcts and less BBB disruption after MCAO (65) reinforces the
idea that early angiogenesis, by destabilizing the BBB, is detrimental to acute
stroke injury and could be a therapeutic target in the future.
Furthermore, because components of the BBB are highly reactive after ischemic
stroke, novel imaging techniques could be used to visualize the ischemic core and
penumbra days after the initial injury. Efforts in this direction have been made,
specifically with gadolinium tagged αvβ3 in both ischemic stroke and myocardial
infarction (Ga-PRGD2) under CT scans (153). Interestingly, researchers were able
to detect αvβ3 differences between control patients and injury patients, up to 14
years post-stroke, but significant differences were observable only up to 3 weeks
post-stroke (124). Furthermore, the amount of αvβ3 correlated to the severity of
the injury, thus the more severe the injury, the more αvβ3 was detectable by CT
with Ga-PRGD2 (153). This technique is in early development, especially for stroke,
as most significant differences were observed in patients who experienced a
myocardial infarction (153), but this establishes precedent for targeting proteins
that are upregulated after stroke.
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Finally, biomarkers for stroke severity and/or BBB dysfunction are highly sought
after as an inexpensive, quick diagnostic. As previously discussed, increased
levels of cellular fibronectin and MMP-9 in the serum could predict hemorrhagic
transformation and severity of bleeding in ischemic stroke patients. Additionally,
the degraded portions of TJ proteins enter the lumen of the vasculature and can
be analyzed in a time dependent manner. Specifically, levels of the TJ protein
occludin increase in the serum by 4.5 hours after ischemic stroke and continue 20
hours later (24 hours after ischemia) (154). Collectively, these potential serum
biomarkers could predict the risk of hemorrhagic transformation after ischemic
stroke, specifically when determining the use of tissue plasminogen activator (tPA).

Conclusion
Taken together, ischemic stroke has a complex multifactorial and spatiotemporal
impact on the BBB. Because of this, previous hopes that targeting any singular
aspect of BBB stroke pathophysiology might produce a “magic bullet” for ischemic
stroke treatment are unlikely to bear fruit. Instead, an effective therapeutic target(s)
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is likely to require multifactorial mechanisms of action on the BBB and multiple
treatments may need to be used in combination to affect such benefit.
Consequently, interest in the BBB, integrins and the ECM, in the context of stroke,
have never been higher, and will undoubtedly lead to novel discoveries and new
stroke therapies in the not-to-distant future.
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Chapter 2: Integrin a5b1 is acutely upregulated on abluminal vasculature in
the core and luminal vasculature in the peri-infarct with unique ligand
binding
Danielle N Edwards, Justin F Fraser, and Gregory J Bix

Introduction
Integrins are heterodimeric transmembrane proteins consisting of 24 diverse a and
b subunits (29). Each integrin combination has a different role in ligand/cell
anchoring, cell signaling, cellular migration, etc. Additionally, the integrin
heterodimers are broken into different ligand partners, such as RGD binding,
laminin binding, and leukocytic integrins (29). Amongst this integrin diversity, one
integrin in particular, a5b1, has shown to be of interest in multiple disease states
including cancer, vascular disease and stroke (46,57,155,159). This is due to the
main role of integrin a5b1, angiogenesis, but also due to its role in cell migration,
cell signaling, and neural tube formation (29, 158). Though expression is highest
during embryonic development, integrin a5b1 expression is reduced to low,
sometimes undetectable levels in maturity until stimulated (57).
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Because of its high impact in angiogenic disease, many cancer pre-clinical and
clinical trials have targeted integrin a5b1 with monoclonal antibodies and the small
peptide inhibitor, ATN-161 (57,156). Due to the increase in antibodies targeting
integrin a5b1, Magnussen et al noticed that antibodies were quickly bound by
accessible integrin a5b1 when intravenously injected (157). They determined that
this may be due to the luminal expression of the integrin in pro-angiogenic tumors.
This result is intriguing as the preferred ligand, fibronectin, is located in the
extracellular matrix on the abluminal vasculature. Furthermore, integrin a5b1 has
a unique synergy binding area, Pro-His-Ser-Arg-Asn (PHSRN). This synergy
region increases integrin a5b1’s affinity (preference) and avidity (bonding strength)
for fibronectin.

Ultimately, we want to determine the therapeutic potential of targeting integrin
a5b1 in stroke based on data our lab found in a5 knockout mice (65). To do this,
we first aim to verify the increase in integrin a5b1 expression in our
tandem/transient ipsilateral common carotid artery/middle cerebral artery
(CCA/MCA) occlusion model. Next, we want to determine the vascular localization
of integrin a5b1 and the potential ligand following experimental ischemic stroke.
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Methods
Animals
All animal studies were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Kentucky prior to their performance.

Stroke Surgery
C57/Bl6 wild-type, male mice underwent transient tandem ipsilateral CCA/MCA
occlusion for 60 minutes as previously published (158), followed by reperfusion for
1-4 days. Briefly, a small burr hole is created directly over the M2 branch of the
MCA, and a metal filament, diameter 0.0005 inch, is placed under the artery on
both sides of the burr hole. The CCA was then isolated and occluded using an
aneurysm clip. Blood flow was determined with the Laser Doppler Perfusion
Monitor (Perimed, Ardmore, PA, USA). Animals that received less than 80%
occlusion rate from baseline (i.e. pre-occlusion) were excluded from analysis.
Sham animals underwent the listed procedure without vascular occlusion. All mice
were allowed to recover to post stroke day (PSD) 3, during which daily body
weights were measured.
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Tissue Histology and Immunohistochemistry
On PSD3, brains were removed, flash frozen in liquid nitrogen, and stored at -20C
until use. The brains were sectioned by cryostat at 20µm and mounted on slides
for staining. Sections were fixed in methanol:acetone (1:1), followed by blocking
buffer (5% bovine serum albumin (Fisher Scientific) in PBS with 0.1% Triton-X).
Sections were incubated in primary antibody overnight at 4C (anti-rat CD49e at
1:250, BD Pharminagen; anti-rabbit collagen IV at 1:250, Abcam; anti-rabbit
Fibronectin at 1:200, Abcam; anti-rabbit Fibrinogen at 1:200. Abcam; anti-rabbit
amyloid b (1-40) at 1:100, Biolegend). Sections were washed and placed in
fluorophore-conjugated secondary antibody at room temperature (Vector Labs,
1:250). Sections were washed and incubated with NucBlue (Fisher Scientific),
cover slipped (Vector Labs) and imaged on a Nikon Eclipse Ti (Nikon, Melville, NY,
USA) or Nikon TI-E C2 Confocal (Nikon, Melville, NY, USA) and software.

Statistical Analysis
All pixel density data was placed at sham threshold for analysis. All measureable
values are presented as mean ± SEM. Sample size was determined for 80% effect
by power analysis. For multiple comparisons, a two-way repeated measures
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ANOVA was used with the posthoc Bonferroni test. Significance is determined as
p*<0.05, p**≤0.01, p***≤0.001, and p****≤0.0001. Outliers were determined by
the interquartile range (IQR).

Results
Integrin a5b1 is upregulated following experimental ischemic stroke.
Following intraluminal ischemic stroke models, infarct volumes are large with no
peri-infarct area while being largely contained to the striatum. In these
experimental conditions, integrin a5b1 expression is shown to noticeably increase
at PSD4, peaks at PSD7, and returns to baseline expression at PSD14 (46,63). In
contrast, our transient occlusion model produces small, cortically limited infarcts
with peri-infarct territory. To determine the expression of integrin a5b1 in our model,
we measured a5 positive pixels (green) on PSD1-4 and sham animals (Figure 2.1).
Analysis showed increased integrin a5b1 expression at PSD2, though not
significantly from sham. From there, integrin a5b1 expression continued to
increase in an exponential way through PSD4 (Figure 1). PSD4 (10955±2340,
n=4) expression was statistically significant upon analysis with one-way ANOVA
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compared to Sham (360±0, n=2; p=0.0089), PSD1 (487.7±105.6, n=3; p=0.0045),
PSD2 (1245±389.3, n=3; 4218±1714, n=4; p=0.0076), and PSD3 (p=0.0452).

Integrin a5b1 is expressed in a location depended manner
Previous studies showed luminally expressed integrin a5b1 on the luminal (apical)
vasculature in tumors (157). To determine the vascular expression, we first
analyzed integrin a5b1 (green) endothelial expression based on arrangement
around the extracellular matrix protein, collagen IV (red), in both the core and periinfarct of perfused animals. The core is the area of initial injury, while the
surrounding peri-infarct region is at risk tissue that has not yet been injured from
the ischemia. In the core, green a5 pixels are seen mostly in association with the
abluminal vasculature, while little remains inside the vasculature integrin a5b1 and
collagen IV co-stain (Figure 2.2A). We then used confocal microscopy to create
models of the vasculature (Figure 2.2B) where we confirmed the abluminally
expressed integrin a5b1.

In contrast to core vessels, microscopy revealed luminally expressed integrin a5b1
in the peri-infarct. This is evident by the representative open vessel in Figure 2.3A,
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Figure 2.1: Integrin a5b1 increases following ischemic stroke. A. a5 positive pixel
analysis on sham and PSD1-4 ipsilateral tissue. B. Representative image of A. 4x
Magnification. Scale bar = 250 μm.
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Figure 2.2: Integrin a5b1 is abluminally expressed in the stroke core. A.
Representative 20x microscopy image of a core vessel. The red box shows
representative images to the right. Green is a5, red is Collagen IV, and DAPI is
blue. Scale Bar =50μm. B. Representative confocal microscopy of a core vessel.
Green is a5 and red is Collagen IV. Scale bar = 20μm.
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Figure 2.3: Integrin a5b1 is luminally expressed in the stroke peri-infarct. A.
44

Representative 20x microscopy image of a peri-infarct vessel. Ted box shows
representative images to the right. Green is a5, red is Collagen IV, and DAPI is
blue. Scale bar = 50μm. B. Representative confocal microscopy of a peri-infarct
vessel. Green is a5 and red is Collagen IV. Scale bar = 20μm.
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where the green a5 pixels are localized predominantly to the luminal space.
Models using confocal microscopy with collagen IV (Figure 2.3B) confirmed this
observation. Importantly, the amount of co-localizing pixels (yellow) was reduced,
again suggesting the lack of integrin a5b1 in the extracellular space on the
abluminal vasculature.

Integrin a5b1 binds a unique ligand in the per-infarct
As mentioned, countless examinations of integrin a5b1 binding have shown a high
preference for fibronectin as a ligand binding partner (156), while other potential
ligands have also been reported. Only the peri-infarct areas were examined due
to lack of tissue/vasculature damage and consistent vascular shape. No colabeling was determined with integrin a5b1 and the potential ligands, plasma
fibronectin (Figure 2.4A), fibrinogen (Figure 2.4B), and amyloid b (Figure 2.4C),
suggesting no binding complexes are present in the peri-infarct.

Discussion
Here, we wanted to determine the therapeutic potential of targeting integrin a5b1
in experimental ischemic stroke through expression and vascular location. We
determined that 1) integrin a5b1 is upregulated acutely following stroke, 2) is
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Figure 2.4: Peri-infarct vessels show no integrin a5b1 binding to fibronectin,
fibrinogen, or amyloid-b. A. Representative confocal microscopy image of a5
(green) and red A. plasma fibronectin, B. fibrinogen, and C. amyloid-b. Scale Bar
= 100μm.
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localized to the luminal vasculature in the per-infarct, but abluminal vasculature in
the core, and 3) in the peri-infarct, integrin a5b1 does not bind plasma fibronectin
in our cortically limited experimental ischemic stroke model. Furthermore, this is
the first study of its kind to determine the vascular localization and binding partner
of integrin a5b1 in experimental ischemic stroke.

Based on the success of the a5 endothelial knockout mice, we intend to target
integrin a5b1 therapeutically. To attempt this, we must first determine when
integrin a5b1 is upregulated in our experimental stroke model. Though this has
been explored in intraluminal suture models, the presentation is comparing white
and gray matter, a significant enough difference that could affect temporal
upregulation. Furthermore, the intraluminal suture model does not possess a periinfarct region with the expansive infarct volumes. This presentation does not model
human stroke, nor the potential for expansion into this at-risk tissue. All of these
factors in concession with the high variability of physiological changes can
significantly affect the temporal expression. Even with multiple competing factors,
the expression of integrin a5b1 in our model is consistent at PSD4. However, we
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did not extend observation through PSD7 and PSD14, so it is plausible the chronic
expression is significantly different from these models.

Targets of interest that are easily accessible to intravenous injections are of high
demand, especially when targeting areas of the brain. The BBB is comprised of
non-fenestrated endothelial cells, extracellular matrix and astrocytic endfeet, all
working together to prevent movement of components from entering the cerebrum
from blood (see Chapter 1 for more information). This hampers access of any
therapeutics larger than 80 Da from accessing the target area, such as
extracellular matrix, astrocytes and neurons. BBB dysfunction has also been
implicated in expanding damage from the core intro the peri-infarct by allowing
cytotoxic and vasogenic edema (16). Interestingly, only integrin a5b1 in the periinfarct region of the stroke, is localized to the luminal vasculature and accessible
to targeted therapeutics. On the other hand, integrin a5b1 is expressed in the
abluminal compartment in the core, away from most therapeutics. This points
toward the potential for binding of integrin a5b1 to a luminally expressed ligand
promoting cellular migration. Another possibility is for bound/unbound integrin
a5b1 to transcytose within intracellular vesicles, though the purpose for this
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hypothesis is less evident. Once bound, integrin a5b1 can become endocytosed
or aid in paracellular migration between endothelial cells to emerge in the
abluminal space and associate with the extracellular matrix. Furthermore, the core
integrin a5b1 expression appears to be outside therapeutic intervention, but early
administration could potentially target a larger peri-infarct region, before damage
has had time to spread.

The localization of integrin a5b1 is not only vital for therapeutic intervention, but
also for potential ligand partners. The preferential ligand for integrin a5b1 is
fibronectin in the extracellular matrix, abluminally expressed. Thus, peri-infarct
expressed integrin a5b1 would be unable to bind this fibronectin. Interestingly,
there are two types of fibronectin, insoluble (basement membrane fibronectin) and
soluble (plasma fibronectin). Both are potential integrin a5b1 ligands as both types
of fibronectin include both the main binding site, RGD, and the synergy site,
PHSRN. In fact, expression of plasma fibronectin has been shown to increase at
PSD2 following experimental ischemic stroke, similar to the observed initial
increase in expression of integrin a5b1 (79). As both types of fibronectin express
the same RGD binding site for integrin a5b1, it was surprising that our
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immunohistochemistry experiments showed no binding to plasma fibronectin in the
peri-infarct. Next, we turned our attention to other vascular ligands shown to
increase following stroke, amyloid b (160) and fibrinogen (161), and again found
no obvious binding. When combining the luminal expression and lack of binding to
common ligands of integrin a5b1, this supports the early stated hypothesis that
integrin a5b1’s role following ischemic stroke is for cellular migration.

In this study, we do have some limitations. First, our experimental design for
integrin a5b1 expression after ischemic stroke only goes to PSD4, while other
studies have shown peaking expression at PSD7 (46). As with the differences
describe above, further experiments need to be performed at PSD7, PSD11,
PSD14 to determine the chronic expression of integrin a5b1 in our experimental
ischemic stroke model. Next, we use only one method of integrin a5b1 localization
and

ligand

binding,

immunohistochemistry.

Processing

tissue

for

immunohistochemistry involves sectioning and washing, potentially displacing
expression of integrin a5b1. Thus, future studies involving electron microscopy
and microvessel isolation could be used to further isolate both vascular localization
and the ligand binding partner of integrin a5b1.
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In conclusion, we determined that integrin a5b1 could be a therapeutic target
following ischemic stroke based on acute increased expression on the luminal
vasculature. Furthermore, once activated, integrin a5b1 bound to a unique ligand
may induce cell migration, leading to vascular remodeling for angiogenesis.
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Chapter 3: The inflammatory response after ischemic stroke: Targeting b2
and b1 Integrins
Danielle N Edwardsv and Gregory J Bix

Introduction
Ischemic stroke is a leading cause of death and disability in the United States with
limited therapeutic interventions available, including tissue plasminogen activator
(t-PA) and endovascular mechanical thrombectomy (1,3-4). These interventions
are focused on the removal of the thrombus, restoring blood flow, oxygen and
glucose to hypoperfused areas, but are unable to affect the inflammatory, necrotic,
and BBB mechanism that follow. In particular, the initial inflammatory cascade is
initiated by the decrease in ATP production, release of cytokines, influx of
intracellular calcium, reactive oxygen species, etc. that develops during occlusion
and continues for days afterword (16,162). Collectively, these processes promote
recruitment

and

infiltration

of

marrow-derived

leukocytes

(including

polymorphonuclear leukocytes (PMNs), neutrophils, lymphocytes and monocytes),
which occurs almost immediately following reperfusion, as movement can only
occur under shear forces from the re-established flow (163-167).
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The initial endothelial response upregulates endothelial selectins, particularly Pselectin and E-selectin, translocating them from an intracellular, inactive state, to
the available extracellular matrix for leukocytic binding, while the upregulation of
L-selectin on the leukocyte is essential for recruitment to the site of injury (168).
Both are acutely regulated, P-selectin at 15 minutes and E-selectin at 2 hours post
ischemia. These extracellularly located selectins then facilitate the recruitment and
activation of leukocytes to the area of ischemia (169). Leukocytes then undergo a
conformational change, facilitating polarization and the development of certain
cellular characteristics: a leading edge, main body, and rear-uropod protrusion.
The uropod in fast moving leukocytes promotes mobility, while the leading
protrusions (lamellipodia and filopodia) are less likely to be used due to the rate
limiting interaction with actin (170-171), though this mechanism is less obvious in
the highly mobile leukocytes. Once leukocytes are bound to selectins, additional
binding to integrins and adhesion molecules (intracellular adhesion molecule
(ICAMs and vascular adhesion molecule-1(VCAM) occurs, permitting leukocytic
rolling (172-175). Additional damage can occur once at the site of ischemia, as
infiltration into the brain parenchyma across the BBB destroys surrounding
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vasculature (176), and leukocytes continually release additional factors (reactive
oxygen species, cytokines, and proteases) that enhance leukocytic recruitment
(177).

At the site of injury, leukocytes continue to increase binding on cerebrovasculature
up to 48 hours following ischemic stroke. Early adhesion, prior to 24 hours
following reperfusion, is attributed to neutrophils. Within 30 minutes to a few hours
following reperfusion, neutrophils arrive at the site of injury, peaking at maximum
expression around 1-3 days, though expression can still be detected 7-15 days
later in preclinical stroke models (178). This upregulation is also seen in ischemic
stroke patients, where neutrophils have been detected beginning at 6 hours, with
radiolabeled imaging, and continue to be detected up to 72 hours (179). The early
recruitment and infiltration of neutrophils across the BBB appears to be highly
significant in stroke, as high neutrophilic infiltration is associated with damaged
cerebrovasculature (180), while depletion reduces infarct volume and dysfunction
in stroke models (181).
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As reperfusion injury continues, the circulating leukocytes switch from neutrophils
to mononuclear leukocytes (monocytes/lymphocytes) dominate the adherent
culture from 24 hours to 7 days post reperfusion (182-184). Of the two types of
lymphocytes, B- and T-, T cells have emerged as the dominant, damage-inducing
lymphocyte in ischemic stroke (185). Preclinical studies have shown the inhibition
of all lymphocytes results in smaller infarct and improved neurological outcomes,
but only the reintroduction of T-lymphocytes to mice reversed any benefits (186188). Activated T-lymphocytes, not B-, have also been detected in patients up to
60 days post-stroke, and are correlated with an increased risk of stroke
reoccurrence and death (189-190).

Multiple studies have established the importance of leukocytic adherence and
infiltration into the brain parenchyma following ischemic stroke, but targeting the
leukocytes has a high degree of risk. This is evident as inhibition of leukocytic cells
increase the occurrence of bacterial and mortality as evident by Leukocytic
Adhesion Deficiency (LAD-1) (164). Because these cells are necessary for
bacterial resistance, systemic inhibition following ischemic stroke is exceptionally
risky. Current attempts at targeting the inflammatory cascade have focused on the
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adhesion and infiltration of cells at the site of injury, primarily endothelial expressed
ICAMs and VCAM. This method has shown success in preclinical studies, but
failure once translated to the clinic (as discussed below). Thus, more focus has
been placed on targeting integrins, a primary mediator of leukocyte adhesion. This
review is focused on integrins, b2 and b1, that have shown promise in
therapeutically targeting the ischemic stroke inflammatory cascade.

Integrins: An overview
Integrins are a diverse group of heterodimers composed of 18 different a and b
subunits, creating 24 unique combinations (191). Integrins exist on every cell type,
while exhibiting a high diversity of ligands, from RGD (Arg-Gly-Asp), laminin, and
leukocytes, though many integrins have a high variety of potential ligands
depending on the cellular environment. Under normal cerebrovascular conditions,
integrins are in a highly inactive state, typically in a bent conformation (192).
Following ischemic stroke, activation signals are sent. Chemokines are
translocated to the lumen, on the apical side of endothelial cells, to induce “insideout” signaling (193-194). Integrins then undergo a conformational change to
increase integrin affinity for potential ligands and are expressed on the either the
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leading or rear-facing edge of the leukocyte’s cell wall for ligand detection
(171,195). Activated integrins then bind to available ligands, permitting leukocytic
rolling and intracellular signaling, termed “outside-in” signaling (193,196).
Leukocytes continue movement to the site of injury, looking for areas to cross the
endothelial cell barrier, and eventually coming to a halt. Aggregation/clustering of
integrins increases binding avidity (strength of binding), preventing flow conditions
from detaching leukocytes from the endothelial cells (193,197). Through
transmigration, leukocytes will infiltrate into the cerebral parenchyma using these
integrin-ligand connections.

b2 integrins

b2 integrins are the only group of integrins exclusively expressed on leukocytes
(derived from hematopoietic cells) (198), and like most integrins, are highly
conserved across species (199). They are also the most highly expressed integrin
on circulating blood leukocytes, tending to cluster at the retraction area of the cell
(the rear), in both an active and inactive state, compared to other b1, b4, b3, and b7
integrins found on circulating leukocytes (200-201). Genetic leukocyte adhesion
changes (LAD-1, as discussed above), have been attributed to mutations in the b2
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subunit, reducing b2 expression. Thus, leukocytic movement is reduced on the cell
surface and less movement toward the site of inflammation (164). Importantly, in
b2 inhibited mice, there is not total arrest of leukocytic recruitment or infiltration
(201), suggesting that other factors likely play a role. There are 4 identified
heterodimers of b2 integrins, aLb2, aMb2, aXb2, and aDb2 (36). Of these, the most
highly studied are aLb2 and aMb2 in ischemic stroke, and will be the reviewed in
more detail below.

aLb2

Integrin aLb2 is also referred to as CD11a/CD18 and LFA-1 (lymphocyte functionalassociating antigen-1). aLb2 integrin acutely increases in ischemic stroke patients,
with detectable amounts through 72 hours associated around the area of ischemia
(202-203). This suggests a correlation between aLb2 integrin expression and
inflammatory damage following ischemia. Though its name suggests otherwise,
aLb2 is expressed on all leukocytes (204), though at particularly high expression
on T-lymphocytes (205-206). After ischemic stroke, aLb2 activation requires
leukocytic rolling on P- or E-selectins, inducing an active conformational change
(207), but it is the binding of chemokines g-protein coupled receptors (GPCR) and

59

Rap-1 activation that induces the high-affinity conformational state of aLb2 (208210). In this state, aLb2 has many possible ligands, ICAM-1, ICAM-2, ICAM-3,
ICAM-4, ICAM-5, and junctional adhesion molecule-1 (JAM-1) (211-214), though
ICAM-1 is preferentially bound (206). Once bound to high avidity aLb2-ICAM-1
complexes form, T-lymphocytes are able to move against circulatory flow and
shear forces, resulting in high-speed movement of leukocytes (215-216).

In experimental models of ischemic stroke, aLb2 inhibition through therapeutic
targeting and genetic manipulation result in reduced infarct volume, edema volume
and mortality, though this phenomenon is evident in transient but not permanent
middle cerebral artery occlusion (217-219). This may be due to the high avidity of
aLb2-ICAM-1 bonds that allow for movement against circulatory flow. This is
evident in aLb2 (LFA-1) knock-in mice that experience high avidity through tight
binding of lymphocytes through ICAM-1 binding as expected, but are unable to
continue movement due to a non-polarized uropod (220). An explanation for this
phenomenon may be that the recycling process within the leukocyte is
overwhelmed (221). By enhancing aLb2 expression, recycling may not be able to
allow for dislocation of aLb2-ICAM-1 complexes, preventing movement from the
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loss of high adhesion bonds. Enhanced aLb2 expression could be a potential new
avenue for therapy, especially if no enhanced mortality, infection, etc. are observed.

Independently, ICAMs play a significant role in inflammation following ischemic
stroke. ICAM-1, in particular, is acutely increased in both cultured human
endothelial cells and following experimental middle cerebral artery occlusion, while
expression remains sustained for up to a week post-injury (222-225). While ICAM2, another possible ligand, does not change in expression following reperfusion
(226). Furthermore, serum of ischemic stroke patients contains soluble ICAM-1,
but not ICAM-2 in addition to being a risk factor (227-228). Antibodies targeting
ICAM-1 in rodents and humans have shown contradictory results. In rodents, mice
and rats showed a decrease in leukocyte infiltration and infarct volume (229-231),
while one study reported opposing effects (232). ICAM-1 inhibition was translated
to the clinic through testing of the murine ICAM-1 antibody, Enlimomab in ischemic
stroke. Unfortunately, the study was halted early due to increased rate of infection,
infarct volumes, neurological scores and mortality for patients (232).
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aMb2

Integrin aMb2 is also known as CD11b/CD18 and Mac-1 (macrophage-1 antigen).
Integrin aMb2 has many similarities to aLb2, through its expression on all leukocytes
(233), and common ligand binding partners such as the family of ICAMs and JAMs
(234). Additional ligands are fibrinogen, heparin (234), elastase (235), complement
C3 fragment (C3bi) (236), kinogen components, and urokinase and its receptor
(237). Just as aLb2, hypoxia induced factors (cytokines, chemokines, etc.) induce
conformational change of aMb2 to a high affinity ligand-binding state (238). Binding
assays with ICAM-1 as a ligand and both aLb2 and aMb2 show aLb2 integrin is
preferably bound (239). This suggests that the binding sites on both aLb2 and aMb2
compete for ICAM-1 binding.

Following experimental ischemic stroke in rats, integrin aMb2 is upregulated (240),
and has shown benefit when inhibited. Antibodies against both CD11b/CD18
reduce infarct volume and reestablished cerebral blood flow as a result of
decreased neutrophil infiltration (225,241-242). In a different approach, the
addition of recombinant neutrophil inhibitory factor (rNIF) inhibits a binding domain
on Mac-1 and yields similar results (243). Furthermore, similarly to aLb2 integrin
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inhibition, inhibition of aMb2 is also effective in transient, but not permanent
experimental ischemic stroke (244).

Clinical Implications
With many successful preclinical trials, across multiple laboratories, clinical trials
were instigated to target b2 integrins. Importantly, no clinical stroke trials to date
have targeted the aL subunit. Though one clinical trial with the monoclonal antibody,
Efalizumab, has shown promise in decreasing T-lymphocyte rolling in patients with
moderate-severe plaque psoriasis (245).

In preclinical studies targeting aMb2, a hookworm isolated recombinant
glycoprotein targeting rNIF (UK279276) (244) and humanized Hu23F2G
(Leukarrest) (246), were both shown to decrease infarct volume and increase
functional recovery following reperfusion.

Both therapies had negligible side

effects in Phase 1 studies and thus were continued to a Phase II study, respectively,
before the trials were halted due to no observed efficacy (247-248). The failure to
target aMb2 integrin may be due to the observation that human ischemic stroke
patients do not experience the increase in aMb2 expression, compared to rodent
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models (249). Interestingly, when given in conjunction with UK279276, patients
experienced a slight improvement (248), but no follow-up has been conducted.
This interesting effect may be worth additional investigation in future clinical trials.

b1 integrins

b1 integrins are a diverse set of integrins, with laminin-binding, collagen-binding,
RGD-binding and leukocyte heterodimers (226). b1 integrins are not as highly
expressed on leukocytes as b2 integrins, but they do play a major role in leukocyte
adhesion and migration following ischemic stroke. The activity of b1 integrins is
similar to b2 integrins. They undergo a conformational change to induce “insideout” and “outside-in” cellular signaling (250). As the cells migrate, the b1 integrins
are most commonly clustered around the uropod, but will be located in any area of
the leukocyte that is in contact with the endothelial cell or extracellular matrix (249250). Inhibition of the b1 integrin, just as with b2 integrin inhibition, does not fully
stop leukocyte rolling. However, when both b1 and b2 integrins are inhibited,
complete leukocyte arrest occurs (201,251). This suggests that both b1 and b2
integrins are necessary for leukocyte migration, regardless of expression load. Of
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all the b1 integrins, both a4b1 and a5b1 appear to be the most highly expressed and
the most studied in inflammatory states.

a4b1

a4b1 is also known as CD49d/CD29 VLA-4 (very late antigen-4). Besides
dimerizing with b1, localizing to leukocytes and microglia, a4 will also dimerize with
b4, which is found in gut endothelium (205). Activation of a4b1 integrin results from
the binding of upregulated chemokines to GPCRs in the same manner as aLb2 as
discussed above (252). This stimulates binding to a4b1’s preferred ligand, VCAM1, but experiments have shown some preference for paxillin and ICAM-1 as well
(208,210). Interestingly, instead of using the b1 submit of the heterodimer for
binding, integrin a4b1 uses its a subunit of a4b1 to mediate binding to VCAM-1 253).

Preclinical ischemic stroke studies targeting a4b1 have shown increasingly varied
results. Most researchers reported a decrease in VCAM-1 expression, cytokine
production, and infiltrating leukocytes (254-256), but this reduction in inflammation
did not result in reduced infarct volumes or functional deficit (256). Langhauser et
al went one step further and found that no treatment paradigm (prophylactic or
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therapeutic) and no model (transient or permanent) showed efficacy (255). On the
other hand, both Becker (247) and Relton (257) found that inhibition of a4 improved
both infarct volumes and functional deficits. When a preclinical randomized control
trial was implemented at multiple centers, researchers found efficacy only in
patients with small infarct volumes (256). Collectively, these contradictory results
may be caused by a couple of scenarios, 1) the varying expression of integrin a4b1
expression following ischemic stroke resulting in continued leukocyte infiltration, or
2) integrin a4b1 is not a primary driver of post-stroke pathophysiology, but other
factors, including other integrins, promote leukocyte migration (205).

a5b1
a5b1 is also known as CD49e/CD29 and VLA-5. Unlike the previously mentioned
integrins, not much is known about a5b1 integrin’s role in inflammation, and what
is known is limited to cell culture. We do know that leukocytes express different b1
integrins with a5b1 composing around 50% of all b1 –integrins expressed, and a5b1
is necessary for leukocyte adhesion. Only inhibition of both a5b1 and b2 integrins
completely blocks adhesion (201), while inhibition of a5b1 alone prevents
transmigration across the BBB (258). Fibronectin is a5b1’s main ligand, and in the
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presence of activated aLb2, leukocyte, its binding to a5b1 is enhanced (259-261).
a5b1 integrin expression is induced by cytokines, particularly TNFa (81) toward the
leading edge of the cell in contrast with other integrins at the uropod (201).
Furthermore, a5b1 integrin appears to be highly sensitive to calcium (201,262), an
ion that is increased rapidly following reperfusion (16). Upon calcium buffering,
a5b1 expression moves from the front of the cell to the uropod and the leukocyte
becomes elongated. The change in expression localization and morphology is
attributed to non-movement as the leukocyte cannot detach a5b1 from the vascular
wall (201). Recently, Edwards et al found inhibition of a5b1 integrin by the small
peptide ATN-161 prevented CD45+ leukocytes from infiltrating the brain
parenchyma. Additionally, mice had reduced BBB permeability, functional deficits,
edema, and infarct volume following middle cerebral artery occlusion (263). Thus,
targeting a5b1 after ischemic stroke could be a new avenue for reduction of
inflammation following ischemic stroke.

Clinical Implications
Even though the results on blocking b1 integrins are small and varied, one clinical
trial has emerged targeting a4b1 in the context of ischemic stroke. The monoclonal
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antibody targeting the a4 subunit (Natalizumab) has been successful in protecting
patients from relapses in multiple sclerosis (264) and Crohn’s disease (265). In a
Phase II study, patients receiving Natalizumab showed no improvement in infarct
growth or neurological scores over 30 days. Furthermore, two patients (out of 79)
died from serious infections attributed to Natalizumab treatment (266). At this time,
there are no further clinical trials planned.

Conclusion
In this review, we have implicated integrins as an area of research for limiting
inflammation following stroke (reviewed in Figure 3.1). To date, therapeutic
inhibition of aLb2, aMb2, and a4b1 has shown promising results in preclinical studies,
but translation to the clinic has been disappointing. Going forward, more targeted
antibodies to all reactive b1 and b2 integrins after ischemic stroke may prove more
beneficial, but more research needs to be done to completely understand the
human inflammatory response and how that relates to changes in preclinical
models.
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Figure 3.1: Representative image of integrin response following stroke and the
effects of inhibitory antibodies.
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Chapter 4: Integrin a5b1 inhibition by ATN-161 reduces blood-brain barrier
permeability, neuroinflammation, and is neuroprotective follwoing ischemic
stroke
Danielle N Edwards, Kathleen Salmeron, Douglas E Lukins, Amanda Trout, Justin
F Fraser, and Gregory J Bix

Introduction
Acute

treatment

for

ischemic

stroke

is

currently

limited

to

recanalization/reperfusion strategies only provided to a minority of patients:
intravenous

tissue

plasminogen

activator

(t-PA)

and/or

endovascular

thrombectomy (1,267-269). While these treatments remove the blood vesselobstructing thrombus, they fail to impact secondary reperfusion injury. Reperfusion
injury results from an influx of factors including calcium, cytokines, reactive oxygen
species, growth factors, matrix metalloproteinases (MMPs), and other damaging
proteins that induce extracellular matrix (ECM) degradation, leukocyte infiltration,
and apoptotic cascades (16,226). These processes destabilize the blood-brain
barrier (BBB), a vascular defense mechanism composed of non-fenestrated
endothelial cells tightly bound by tight junction (TJ) proteins and junctional
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adhesion molecules (JAMs), that are surrounded by astrocytic endfeet16,226,270).
Collectively, this results in an increase of the infarct volume from the site of the
initial injury (core) into the surrounding at-risk tissue (peri-infarct). Therefore,
targeting reperfusion injury could alter ischemic stroke outcomes.

One such potential target is the integrin receptor family, a group of cell surface
transmembrane glycoprotein receptors for the ECM composed of non-covalently
bound α and β subunits. Vital to stroke pathophysiology, integrins have been
implicated in cell migration, cellular adhesion, and cellular survivability (271-272).
Previously, our laboratory has shown that elimination of the specific pro-angiogenic
integrin α5β1 in endothelial specific knockout (α5KO) mice results in significance
resistance to ischemic stroke injury. Furthermore, these α5KO mice maintained
near-baseline pre-stroke levels of the TJ protein claudin-5 and exhibited little to no
disruption of the BBB barrier (65). These results, combined with previous studies
demonstrating a sustained increase in the post-stroke expression of integrin
α5β1 (63,273), suggest that inhibition of α5β1 integrin could be therapeutic by
stabilizing the BBB. Early intervention of the BBB following ischemic stroke is ideal,
as its role in injury is not immediately apparent (274). To that end, in this study we
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use the small peptide non-competitive integrin α5β1 inhibitor, ATN-161, in a
mouse model of ischemic stroke. ATN-161 is a non-competitive inhibitor targeting
the integrin α5β1 allosteric site, PHSRN (Proline-Histidine-Serine-ArginineAsparagine), instead of the main RGD binding site. Importantly, ATN-161 was safe
and well-tolerated in a number of Phase I and II clinical oncology studies (159),
supporting its potential as a ‘shovel-ready’ clinical stroke therapeutic.

Materials and Methods
Animals
All animal studies were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Kentucky prior to their performance. 3month old C57/Bl6 (The Jackson Labs, Bar Harbor, Maine, USA) were housed in
14-hour day/light cycles under free feeding conditions 10 days before being used
in experiments.

Stroke Surgery
C57/Bl6 wild-type, male mice underwent transient tandem ipsilateral common
carotid artery / middle cerebral artery (CCA/MCA) occlusion for 60 minutes as
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previously published (65), followed by reperfusion for 1-3 days. Briefly, a small burr
hole is created directly over the M2 branch of the MCA, and a metal filament,
diameter 0.0005 inch, is placed under the artery on both sides of the burr hole. The
CCA was then isolated and occluded using an aneurysm clip. Blood flow was
determined with the Laser Doppler Perfusion Monitor (Perimed, Ardmore, PA,
USA). Animals that received less than 80% occlusion rate from baseline (i.e. preocclusion) were excluded from analysis. Sham animals underwent the listed
procedure without vascular occlusion. All mice were allowed to recover to PSD3,
during which daily body weights were measured.

ATN-161 Preparation
ATN-161 (Medkoo Biosciences, Inc, Morrisville, NC, USA) is stored as a
lyophilized powder at -20C. On the day of treatment, ATN-161 is solubilized in PBS,
kept cold on ice until use not exceeding 3 hours later. A new vial of ATN-161 is
used for each different day of treatment.
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Physiological Measurements
Immediately following reperfusion, heart, rate, pulse distension, and body
temperature were recorded using MouseOx (Starr Life Science, Holliston, MA,
USA). After 5 minutes, sterile PBS (Vehicle) or ATN-161 was injected via IP (as
described below); mice were continually observed for 15 minutes post reperfusion.

Animal Treatments
Animals received an IP injection of either Vehicle or ATN-161 (1mg/kg (156) in
sterile PBS, Medkoo Biosciences, Morrisville, NC, USA) immediately after
reperfusion, PSD1 and PSD2. Ischemic stroke was confirmed on 2mm sections
stained with 2,3-triphenyltetrazolium chloride (TTC; BD, Sparks, MD, USA) or
Magnetic Resonance Imaging on PSD3. Accounting for edema volume, infarct size
based on TTC images was analyzed with Image J (NH) software as:
Infarct volume = infarct x (

Contralateral Hemisphere
)
Ipsilateral hemisphere

Animals were excluded from the study if the CCA and/or MCA was punctured
during wire and clamp placement or removal.
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Magnetic Resonance Imaging (MRI)
PSD3 animals were anesthetized with isoflurane and placed on a heated bed
where body temperature and breathing rate were carefully monitored throughout
the scan. All images were performed by a Bunker/Siesman 7Tesla MR in the
University of Kentucky Magnetic Resonance Imaging and Spectroscopy Center.
T1 and T2 weighted images of the brain were obtained in the transverse plane
without intravenous contrast. Additionally, Apparent Diffusion Coefficient (ADC)
images were produced in the transverse plane using Diffusion Tensor Imaging
(DTI). All images were analyzed with ITK-SNAP (275) (www.itksnap.org) by a
blinded, independent neuroradiologist. Edema and infarct volume were
determined by software based manual segmentation. Infarct enhancement was
calculated by analysis of absolute signal intensity on T1 weighted images before
and after the administration of gadolinium based contrast material.

Tissue Histology and Immunohistochemistry
On PSD3, animals were systemically perfused with PBS (Phosphate Buffered
Solution, 1X) for 5 minutes. Brains were removed, flash frozen in liquid nitrogen,
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and stored at -20C until use. The brains were sectioned by cryostat at 20µm and
mounted on slides for staining.

IgG Immunohistochemistry
Sections were fixed in 10% phosphate-buffered formalin. After washing, IgG 568
biotinylated antibody (1:500, Thermo-Fisher Scientific) in 1% bovine serum
albumin was applied to the tissue for 2 hours. Slides were then cover slipped
(Vector Labs) for imaging on a Nikon Eclipse Ti and software (Nikon, Melville, NY,
USA).

Immunohistochemistry
Sections were fixed in methanol:acetone (1:1), followed by blocking buffer (5%
bovine serum albumin (Fisher Scientific) in PBS with 0.1% Triton-X). Sections were
incubated in primary antibody overnight at 4C (anti-rabbit PECAM at 1:100, Fisher
Scientific; anti-rat CD49e at 1:250, BD Pharminagen; anti-rat CD45 at 1:200,
ThermoFisher Scientific; and anti-rabbit Claudin-5 at 1:200, Abcam). Sections
were washed and placed in fluorophore-conjugated secondary antibody at room
temperature (Vector Labs, 1:250). Sections were washed and incubated with
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NucBlue (Fisher Scientific), cover slipped (Vector Labs) and imaged on a Nikon
Eclipse Ti and software (Nikon, Melville, NY, USA).

Behavioral Testing
Stroked mice underwent an 11-point behavioral neurological score behavioral
assessment on PSD0 (Baseline prior to drug administration), PSD1, 2, and 3 to
assess the following behavioral metrics: level of consciousness (LOC), gaze (G),
visual field (VF), sensorimotor response (SR), grip strength and endurance/
paralysis paw hang (PPH). LOC was determined as natural movement prior to any
cage disturbance. A severity score of 0-2 was assigned, 0 being alert and active,
1 alert upon stimulation, and 2 for being hunched, unstimulated, and loss of
grooming. Gaze was assessed by waving an object in front of each eye without
disturbing the whiskers. Based on a severity score of 0-1, 0 was given if they
recognized the sign by turning their head, and a 1 was given if no response was
noted. VF was assessed holding the mouse vertically next to a platform by the tail
(both right and left sides). A score of 0 was given if the mouse reached for the
platform, and a 1 for failure to do so. SR was scored by pressing each paw in turn
to elicit vocalization, paw retraction, or jumping as a reaction to pressure. A score
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of 0 was given for exhibiting a reaction, and a 1 for no reaction. Finally, PPH was
scored by a paw hang test. Only front paws were used for gripping of a rod while
being supported by a hold on the tail for 60 seconds. A score of 0 was given for
completion of the full 60 seconds, a 1 for any dropping of a paw without full loss of
contact, and a 2 for a fall. The total scores are tallied at the conclusion of the testing
to assess overall function.

Gene Expression
On PSD3, brains were removed and sectioned at 2mm where the ipsilateral
cortical tissue and corresponding contralateral cortical tissue were isolated. All
sections per animal were combined and homogenized in Trizol (Life Technologies).
RNA extraction was performed according to the RNA extraction kit provided by the
manufacturer (Life Technologies). RNA was converted to cDNA using a high
capacity cDNA reverse transcriptase kit (Applied Bioscience, Grand Island, NY,
USA). 18S (control), claudin-5, IL-1𝛽, CXCL12, and MMP9 genes were analyzed
using Real-time PCR (ViiA7, Life Technologies). Data was analyzed as fold
change comparing vehicle and ATN-161 treated mice as a % control (sham).
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Blinding and Randomization
All experiments and data analysis were conducted in a blinded and randomized
(using an online randomization generator).

Statistical Analysis
All measureable values are presented as mean ± SEM. Sample size was
determined for 80% effect by power analysis. Comparisons between Vehicle and
ATN-161 treatment were performed using a Student’s t-test. For multiple
comparisons, a two-way repeated measures ANOVA was used with the posthoc
Bonferroni test. Significance is determined as p*<0.05, p**≤0.01, p***≤0.001, and
p****≤0.0001. Outliers were determined by the interquartile range (IQR).

Results
ATN-161 treated mice show reduced infarct size following experimental ischemic
stroke
First, we examined whether acute, post-reperfusion IP ATN-161 administration
was safe. ATN-161 treated animals did not show any differences in weight (Figure
4.1A), body temperature (Figure 4.1B), heart rate (Figure 4.1C), or pulse
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Figure 4.1: Systemic effects of ATN-161 administration. A. Percent change of
weight (g) through PSD3. B. Percent change of body temperature (℃) following
reperfusion. C. Percent change of heart rate (bpm) following reperfusion. D.
Percent change of pulse distension (μm) following reperfusion.
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distension (Figure 4.1D) following ischemic stroke compared to Vehicle treated
stroked controls.

Once safety was determined, stroked mice were IP administered Vehicle or ATN161 immediately after reperfusion, on PSD1, and PSD2 (Figure 4.2A). By TTC
assessment, mice treated with ATN-161 had smaller infarcts on PSD3 (Figure 4.2B
and Figure 4.2C; p=0.0004; ATN-161 16.37±4.113, n=12; Vehicle 35.41±4.054,
n=12).

To further confirm potential ATN-161 effects on infarct volume in a translationally
relevant manner, stroked mice underwent DTI imaging on PSD3. Infarct volume
was again shown to be reduced in ATN-161 treated mice (Figure 4.3A and
Figure 4.3B; p=0.0220; Vehicle 17.9±1.768, n=7; ATN-161 12.24±1.329, n=8).
Collectively the TTC and DTI analysis shows a decrease in infarct volume following
ATN-161 treatment.

ATN-161 administration reduces edema following experimental ischemic stroke
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Figure 4.2: ATN-161 reduces infarct volume and improves functional recovery. A.
Injection schematic B. Representative images of C. TTC analysis of infarct volume
at PSD3. Images has been altered to line up the sections.
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Figure 4.3: ATN-161 reduces MRI infarct volume and edema. A. Representative
DTI images. B. DTI analysis for infarct volume. Arrows indicate infarcted region. C.
Representative T2-weighted MRI images. Arrows indicate edematous region. D.
T2-weighted MRI analysis for edema volume.
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In addition to infarct volume, we also determined the extent of post-stroke edema
with T2-weighted MRI. Imaging showed a reduction in edema in ATN-161 treated
mice (Figure 4.3C and Figure 4.3D; p=0.0097; Vehicle 15.12±1.212, n=7; ATN161 8.777±1.647, n=8). Interestingly, the ATN-161 treated mice, but not the
Vehicle group, showed a linear correlation relationship between infarct volume and
edema volume (Figure 4.4C; ATN-161 p=0.0072, 𝑅= =0.7264) (Figure 4.4B;
Vehicle p=0.0786, 𝑅= =0.4931) (All treatments, Figure 4.4A). This suggests that
integrin α5β1 plays a role in the extent of edema following ischemic stroke.

ATN-161 treated mice have better functional outcomes
ATN-161 treated mice showed less functional deficit on PSD3 by Neuroscore
(Figure 4.5A; p=0.0002; Vehicle 2.286±0.19, n=14; ATN-161 3.286±0.22, n=14),
while there is no difference on PSD1.

ATN-161 reduces α5β1 expression following ischemic stroke
α5β1 integrin expression decreased at PSD3 with ATN-161 administration in both
the peri-infarct (Figure 4.5B and Figure 4.5D; p=0.0835, Vehicle 308484±72853,
n=7; ATN-161 162166±26469, n=7) and core (Figure 4.5C and Figure 4.5D;
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Figure 4.4: ATN-161 influences edema volume. A. Linear correlation of infarct
volume and edema volume for all treatments. B. Linear correlation of infarct
volume and edema volume for Vehicle treated animals. C. Linear correlation of
infarct volume and edema volume for ATN-161 treated animals.
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Figure 4.5: ATN-161 reduces integrin α5β1 expression. A. 11-point Neuroscore
analysis at baseline, PSD1, and PSD2. Analysis of integrin α5β1 at PSD3 in the B.
core and C. peri-infarct. D. Representative images for B. and C.10x magnification,
scale bar = 100μm.

86

p=0.3138, Vehicle 332114±7915, n=7; ATN-161 233111±51006, n=7) regions of
the stroke, although these differences were not significant. Interestingly, ATN-161
had an increased effect on α5β1 integrin expression in the region ventral to the
injury (Figure 4.6A; Figure 4.6B; p=0.1092; Vehicle 384123±106607, n=7; ATN161 190693±33630, n=7) compared to the region dorsal to the injury (Figure
4.6C)p=0.0340; Vehicle 212647±28412, n=7; ATN-161 126903±21841, n=7).

ATN-161 reduces BBB permeability following experimental ischemic stroke
Since α5KO mice showed a stabilized BBB after experimental stroke10, we next
determined BBB stability via brain IgG extravasation following ATN-161
administration. ATN-161-treated animals had significantly less parenchymal IgG
extravasation in the ischemic core (Figure 4.7A and Figure 4.7B; p=0.0234;
Vehicle 70125±20216, n=7; ATN-161 16753±8255, n=8). Interestingly, ATN-161
treated mice experienced a correlation between IgG extravasation (i.e. degree of
BBB opening) and edema (Figure 4.7D; p=0.0590, 𝑅= =0.474) that was lost with
Vehicle treated mice (Figure 4.7C; p=0.3705, 𝑅= =0.1621). However, IgG
extravasation and infarct volume did not correlate in either Vehicle (p=0.9732,
𝑅= =0.0002498) or ATN-161 (p=0.1309, 𝑅= =0.3377) treated mice. This suggests a
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Figure 4.6: Integrin α5β1 expression in the peri-infarct region. A. Representative
image for region of interest dorsal (blue) and ventral (green) to the core (pink).
Images were analyzed for integrin α5β1 expression B. dorsally and C. ventrally to
the stroke.
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Figure 4.7: ATN-161 reduces BBB permeability following ischemic stroke. A.
Representative images of A. 20x magnification, scale bar = 50μm. B. Analysis of
IgG positive pixels in the core. C. Linear correlation between IgG positive pixels
after vehicle treatment and Edema Volume. D. Linear correlation between IgG
positive pixels after ATN-161 treatment and Edema Volume.
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direct role for integrin α5β1, and its blockade, in determining the amount of edema
following ischemic stroke due to regulating dysfunction of the BBB. Collectively,
reduced infarct volume may be a consequence of inhibition of integrin α5β1
through a less permeable BBB, and thus reduced edema.

Next, to determine integrin α5β1's role in cerebrovascular pathology after stroke,
we analyzed changes in vascular ECM proteins, proteinases that degrade the
ECM, and TJs. On PSD3, Vehicle treated mice exhibit decreased collagen IV (an
abundant ECM protein that is essential to BBB health) transcription compared to
sham (p*=0.0115) and ATN-161 (p=0.0217) treated animals (Figure 4.8A; Sham
1.018±0.07867, n=4; Vehicle 0.3543±0.03829, n=7; ATN-161 0.8563±0.2439,
n=8), while ATN-161 treated animals were recovered to sham levels (p=0.7272).
We next determined that MMP-9 (an ECM proteinase that typically increases after
stroke) levels are increased in Vehicle treated animals compared to Sham
(p=0.0028) and ATN-161 (p=0.0156) treated mice (Figure 4.8B; Sham
1.018±0.08797, n=4; Vehicle 6.761±2.011, n=7; ATN-161 2.757±0.9076, n=7),
though no significance between Vehicle and ATN-161 treated mice (p=0.5238).
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Figure 4.8: ATN-161 stabilized cerebrovasculature following ischemic stroke. A.
qPCR analysis of ipsilateral cortex at PSD3 for collagen IV. B. qPCR analysis of
ipsilateral cortex at PSD3 for MMP-9. C. Representative images of D. 10x
Magnification, scale bar = 100μm. D. Analysis for Claudin-5 positive pixels in the
core at PSD3.
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Finally, we determined that ATN-161 treatment resulted in an increase of claudin5 in the core (Figure 4.8C and Figure 4.8D; p=0.0270; Vehicle 19830±2477, n=5;
44220±8115, n=6). Collectively, inhibition of α5β1 by ATN-161 stabilizes the
vasculature at the site of injury (increased collagen IV, MMP-9, and claudin-5
expression) and results in a more intact BBB (less IgG extravasation) following
ischemic stroke.

ATN-161 reduces the inflammatory response in the infarcted region
Inflammatory cascades occur acutely and last for up to a week after stroke. This
involves an increase in inflammatory cytokines and neutrophil infiltration, all
localized to the core site of injury (16). Furthermore, integrins have been implicated
in many inflammatory processes (272). To determine ATN-161’s potential effects
on post-stroke inflammation, we first determined its effects on the expression of
the master inflammatory cytokine, IL-1β, which is well known to be upregulated
after experimental ischemic stroke (276). Indeed, we determined that IL-1 β
transcription is increased in the Vehicle treated mice compared to sham (Figure
4.9A; p=0.0006; Sham 1.023±0.0833, n=4; Vehicle 27.04±7.057, n=8). ATN-161
administration, significantly reduced (p=0.0192; ATN-161 11.89±3.491, n=7)

92

Figure 4.9: ATN-161 reduces inflammatory cells after experimental ischemic
stroke. qPCR analysis of ipsilateral cortex at PSD3 for A. IL-1β and B. CXCL12.
C. Representative images of D. 4x Magnification, scale bar = 250μm. D. Analysis
for CD45 positive pixels at PSD3.
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(Figure 4.9A) IL-1β expression. Investigating the chemokine ligand 12 (CXCL12),
previously shown to be protective following ischemic stroke (277), we found that
Vehicle treated mice had reduced transcription of CXCL12 compared to sham and
ATN-161

(Figure

4.9B;

p=0.0022;

Sham

1.015±0.09819,

n=4;

Vehicle

0.5271±0.06725, n-7; ATN-161 0.8488±0.1006, n=8), while ATN-161 treated mice
recovered CXCL12 to sham levels.

Additionally, integrins have not only been implicated in cytokine and chemokine
expression, but also in migration of inflammatory neutrophils to the site of injury, a
mechanism highly implicated in edema and expansion of the core (16,226). Even
though neutrophils have the highest significance of all leukocytes trafficking to the
site of injury, all categories of leukocytes have a role (156). Because of this, we
determined the effect of ATN-161 on CD45, a pan leukocyte marker, at PSD3 via
immunofluorescence. Again, fewer infiltrating cells were found in the ipsilateral
stroked brain parenchyma with ATN-161 treatment (Figure 4.9C and Figure 4.9D;
p=0.0225; Vehicle 499674±109793, n=7; ATN-161 215451±37499, n=8). Taken
together, inhibition of integrin α5β1 with ATN-161 reduces the inflammatory load
following ischemic stroke.
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Discussion
Our goal was to determine the therapeutic potential of blocking the α5β1 integrin
with ATN-161 in experimental ischemic stroke. ATN-161 has been previously
described as an anti-angiogenic therapeutic, where the safety and efficacy of ATN161 have been described in cancer pre-clinical research and clinical trials (159).
Here, we demonstrated that ATN-161 treatment led to decreases in infarct volume,
edema, and functional deficit through inhibition of the integrin α5β1 following
experimental ischemic stroke. Furthermore, we found that post-stroke ATN-161
administration stabilizes the BBB as evidenced by decreased IgG extravasation,
stabilization of collagen IV and claudin-5 expression, as well as significantly fewer
infiltrated leukocytes, and decreases in both MMP-9, CXCL12, and IL-1β mRNA
expression. These results are consistent with our previous studies using
endothelial selective α5KO mice that demonstrated that these mice were
profoundly resistant to ischemic injury and BBB disruption (65). To our knowledge,
the current study is the first to demonstrate therapeutic efficacy of inhibiting integrin
α5β1 in ischemic stroke.
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Importantly, ATN-161-mediated effects on function only occurred after all three
injections were administered. This suggests a need for continuous acute and
subacute inhibition of integrin α5β1 following ischemic stroke to inhibit any
intermittent vascular remodeling that may occur. “Flooding the system” with ATN161 is possible as previous clinical trials (Phase I and II for tumorigenesis) showed
limited side effects (dry mouth, cellulitis, and paresthesia at 1 mg/kg 10-minute
infusions for one out of four patients) (156,159,278). Our findings further support
the reported safety of ATN-161 with our treated mice exhibiting no physiological
differences (Figure 4.2) compared to their controls. ATN-161 has been shown to
bind not only integrin α5β1, but also integrins αvβ3 and α6β1, though preference
is for integrin α5β1 when highly expressed )156). Furthermore, integrin αvβ3 and
α6β1 expression after stroke is more acute and very brief, potentially limiting the
non-specificity of ATN-161 (279).

In this study, we used only one dosage of ATN-161 (1mg/kg via IP injection) based
on previous research by Donate et al. which showed that ATN-161 exhibits a Ushaped dose response curve in vitro, where doses equivalent to 1-5 mg/kg
produced the most significant reduction in activity (angiogenesis and tumor growth),
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with 1 mg/kg being the most effective (156). Therefore, additional stroke doseresponse studies should be performed. Likewise, additional studies addressing
ATN-161’s therapeutic window, and potential long-term effects, need to be
conducted.

Upon ATN-161 administration, we found less IgG extravasation in the brain
parenchyma, in agreement with our results in stroked α5 KO mice that also
exhibited little/no post-stroke IgG extravasation. The decreased IgG extravasation
is indicative of reduced BBB permeability as normal paracellular transport allows
free passage of 80 Da proteins, while IgG is size limited at 150 kDa (16,279-280).
BBB stability, especially TJ integrity, is severely compromised following ischemic
stroke (281). Osada et al implicated β1 -integrins as major regulators of tight
junction expression and BBB permeability, particularly claudin-5 (70). Further
analyses showed a significant increase in claudin-5 (tight junction) and collagen IV
(ECM) protein, while ECM degradation protein, MMP-9, decreased. Inhibition of
integrin α5β1 via ATN-161 also resulted in reduced IL-1β expression and fewer
infiltrating CD45+ leukocytes. Leukocytes (neutrophils, monocytes, macrophages,
etc.) are highly implicated in increasing edema through adhesion of β2 integrin
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(282-285). However, under inflammatory conditions, neutrophils show increased
expression of integrin α5β1 located in intracellular vesicles and promote neutrophil
migration through recycling (201,259,285-286). Furthermore, decreased integrin
α5β1 levels have been shown to reduce monocytic binding as well as decreased
IL-1β and MMP-9 expression on leukocytes (201,284,287). Decreased leukocytic
MMP-9s are associated with reduced BBB leakage, reduced collagen IV
proteolysis, decreased neutrophil infiltration, and a relative absence of
hemorrhagic transformation (288). Additionally, we observed conservation of
CXCL12 transcription post-stroke with ATN-161 administration. The chemokine,
CXCL12, has been shown to be protective in hypoxia pre-conditioning by
anchoring astrocytic endfeet to BBB proteins, thus reducing leukocytic infiltration
and increased BBB permeability (277). Our results suggest that integrin α5β1 may
play a significant role in regulating claudin-5 expression in endothelial cells, while
also regulating neutrophilic infiltration and the associated mechanisms of BBB
breakdown (such as IL-1β and CXCL12 transcription and collagen IV proteolysis).

As integrin α5β1 is pro-angiogenic, long-term inhibition may prove to be
deleterious as previous studies have shown that patients with increased vascular
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density tend to have better stroke outcomes (152,280,289). Furthermore, studies
using angiogenic promotors, particularly VEGF, resulted in increased, leaky
vessels with no impact on infarct volume when induced post-stroke (152,272).
Collectively, this confirms that timing is everything regarding post-stroke
angiogenesis. As vascular remodeling and pruning involves disassembly of brain
vessels, it leaves those vessels vulnerable to the influx of inflammatory cells,
cytokines, and reactive oxygen species, which are all known to exacerbate
damage. Thus, early inhibition of endothelial cell activation / angiogenesis via ATN161 may be beneficial in prohibiting the inflammatory cascade and BBB breakdown,
while the short half-life (3-4.5 hours) could allow for future angiogenesis to proceed
(159). This may also allow for the intriguing possibility of combining early / acute
inhibition of α5β1 integrin with its later activation to collectively limit early injury and
subsequently promote angiogenic neurorepair.

Intriguingly, our results are seemingly in direct contrast to a recent study
demonstrating that administration of a single IP dose of the small peptide α5β1
integrin agonist PHSRN, 24 hours after rat transient MCAO was both
neuroprotective, proangiogenic and increased neurogenesis (290). In their study,
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they noted that PHSRN increased α5 integrin expression on PSD3 (in contrast we
noted that ATN-161 decreased α5 integrin on PSD3), and activated several known
downstream signaling agents of α5β1 including pFAK, p-C-Raf, Ras, pERK, and
VEGF, the latter of which was speculated to be the primary mechanism of
therapeutic benefit. Furthermore, they did not examine any aspects of the BBB,
edema, or inflammation, but rather speculated that initiating treatment 24 hours
after stroke would alleviate potential deleterious effects of upregulated VEGF on
the BBB.

These seemingly contrasting results may be reconciled by pointing out several
differences between the two studies. Besides the obvious differences (rat versus
mouse transient MCAO model, single versus repeated dosing, etc.), ATN-161 is
known to preferentially target and interact with the activated form of α5β1 integrin,
i.e. that which is present in the brain after stroke, while PHSRN shows no
predilection for any particular α5β1 integrin state (156). Therefore, it cannot be
ruled out that some, or even a significant extent of PHSRN’s post-stroke effects
seen by Wu et al could be due to off-target non-cerebral α5β1 or integrin αvβ3
(179) integrin interactions. Indeed, Wu et al hint at a potential PHSRN interaction

100

in the liver as a confounding factor, but failed to show any systemic effects after
PHSRN administration. A therapeutic benefit of agonizing, or enhancing, α5β1
integrin after stroke is also inconsistent with our findings that α5β1 integrin
endothelial-cell specific KO mice are profoundly resistant to ischemic brain injury
(65). Finally, previous studies have shown PHSRN to have inhibitory effects on
integrin binding to fibronectin as both the synergy region (PHSRN) and RGD are
necessary (291). In any event, an emerging body of evidence appears to indicate
that modulating (activating or inhibiting) α5β1 integrin after ischemic stroke could
be therapeutic.

Limitations of our study include the fact that our transient MCA occlusion model
produces reproducible, but small and cortically limited infarcts which could
minimize ATN-161’s therapeutic effects (stroke volumes cannot be determined as
smaller than zero). Furthermore, these small infarcts show limited motor and
sensory effects, thus hampering our ability to test behavioral deficits past the
maximum expansion at PSD3. Therefore, follow-up studies should include
additional stroke models as well as the study of aged, female and co-morbid
animals as per the STAIR recommendations (267).
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Conclusion
Our studies show that inhibition of α5β1 integrin with ATN-161 is beneficial
following experimental ischemic stroke through reduction of infarct volume and
edema, while also transiently increasing functional outcomes. Furthermore, ATN161 stabilizes the BBB, and reduces inflammation / immune cell infiltration into the
brain. Collectively, our results suggest that ATN-161 may be a promising, novel
therapeutic for ischemic stroke.
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Chapter 5: Discussion
In this chapter, I will briefly overview results from Chapters 2 and 4. Next, I will
address limitations of the studies discussed above. Next, I will address the
potential mechanism of action we believe integrin a5b1 works through following
ischemic stroke. Finally, I will address limitations of the current studies, and
present future directions.

Summary
Current therapies for ischemic stroke, t-PA and endovascular thrombectomy, are
focused on removal of the thrombus, but do not address increased inflammation,
BBB dysfunction, or any other pathologic mechanism after reperfusion. In
particular, increased infarct volume and worsened patient outcomes have been
implicated with decreased BBB dysfunction (16). Using the first line of BBB
defense, endothelial cells, endothelial integrins, particularly the family of b1
integrins, have been implicated in TJ expression and neurovascular remodeling
(70, 292). Previously in our lab, absence of the b1 integrin a5b1 in endothelial cells
is neuroprotective against ischemic stroke. This was attributed to conservation of
claudin-5, leading to a stabilized post-stroke BBB as determined by IgG staining

1

(165). Following experimental ischemic stroke, we therefore formed two
hypotheses: 1) inhibition of integrin a5b1 would result in smaller infarct volumes
and better outcomes and 2) the BBB would be less permeable with less active
integrin a5b1.

Before we moved toward therapeutic inhibition, we wanted to determine if integrin
a5b1 was acutely upregulated in our stroke model. We found an increase in
integrin a5b1 beginning at PSD2 with expression continually increasing to PSD4.
These results are similar to other reported experimental stroke and hypoxia models,
as discussed in Chapter 2. Next, we determined if the upregulated integrin a5b1
was accessible to administered therapeutics, a common issue when targeting the
cerebrum. This is vital when introducing compounds that target the brain. The BBB
prevents free movement of molecules larger than 80 Da, thus limiting most
therapeutics that need to reach the brain parenchyma (226). Intriguingly, integrin
a5b1 vascular localization was observed to be region dependent. When looking in
the peri-infarct, integrin a5b1 appears to be located in the vascular lumen, while
expression in the core shifted to the abluminal compartment at PSD3.

It is

important to distinguish that our model does not reach full evolution of the stroke
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(i.e. the largest the stroke will become) until PSD3. Thus, these collective results
suggest the expression of integrin a5b1 in the non-damaged tissue (peri-infarct) is
a good indicator of integrin a5b1 immediately upon reperfusion. However, further
investigation at reperfusion, PSD1 and PSD2 would provide insight into the
movement of integrin a5b1 as its’ expression increases.

Lastly, the vessels in the peri-infarct failed to show fibronectin, fibrinogen or Ab
binding (co-localization) to integrin a5b1. This, in addition to the varying
localization of integrin a5b1, suggests a potential new role of integrin a5b1
following reperfusion. Because of the divergent vascular presentation of integrin
a5b1, a couple of mechanisms could be used to explain the purpose for this
movement. One possibility is the activation of integrin a5b1 by reperfusion
mechanisms (HIF-1a, ATP depletion, etc.) and use transendothelial migration to
travel from the apical to basal endothelium for basement membrane fibronectin
binding. Interestingly, integrin a5b1 has been found in caveolin-1 intracellular
vesicles, implicating this possibility (293). Another potential hypothesis is the
participation of integrin a5b1 in the inflammatory cascade. Specifically, leukocyte
migration to the area of damage and infiltration into the parenchyma. Currently,
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evidence points to integrin a5b1 having an inflammatory role (discussed in more
detail below), but investigation into transendothelial migration still needs to be
determined.

Once we determined the potential of therapeutic targeting of integrin a5b1 in our
experimental stroke model, we tested our first hypothesis on the effectiveness of
the small peptide ATN-161 in experimental ischemic stroke. This integrin a5b1
inhibitor we selected is an FDA-approved small peptide, ATN-161. ATN-161
targets the PHSRN, or synergy region, of integrin a5b1, which increases the
binding affinity of integrin a5b1 for fibronectin over other RGD binding integrins
(integrin avb3, a6b1, etc.). ATN-161 is reported to have an inverted U-dose
therapeutic curve, where doses of 1 mg/kg - 5 mg/kg (particularly the 1 mg/kg
dose) are the most effective in preventing integrin a5b1 mediated angiogenesis
(156).

Additionally, ATN-161 has been used in solid tumor clinical trials. Though no
significant benefit was determined, ATN-161 is proven to be safe. When
administered by IV infusions over a two-week period, the most serious side effects
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reported were paresthesia, nausea, sweating (159). Ischemic stroke is a different
model with different pathophysiology, we needed to determine the safety of ATN161 before further steps could be taken. After the first dose of IP injected, 1 mg/kg
ATN-161, we detected no significant changes in animal weight, heart rate, pulse
distension (comparable to blood pressure), or body temperature when compared
to Vehicle treated controls. Lastly, when observed over three days, no significant
change in weight was reported.

In addition to determining the dose, we performed many trials to determine the
dosing frequency of ATN-161. Initially, we used the expression of integrin a5b1
and the irreversible binding of ATN-161 (156) as a guide. Thus, we hypothesized
that PSD1 administration of ATN-161 would be sufficient to prevent the increase
observed at PSD2. However, multiple experiments showed inconsistent benefit (i.e.
some mice showed infarct volumes comparable to vehicle treated mice, while
others showed ~90% reduction) (Figure 5.1A). We hypothesized that we missed
the early upregulation of integrin a5b1 in some of the animals. Next, we attempted
ATN-161 administration immediately after reperfusion and on PSD1. Again, we
saw no benefit with the two-dose structure (Figure 5.1B). We suspected this may
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Figure 5.1: Infarct volume for variable ATN-161 dosing. Infarct analysis of TTC
stains from IP injection on A). PSD1 only and B). IP immediately following
reperfusion and PSD1.
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be attributed to the inability of ATN-161 to completely prevent the strong
upregulation of integrin a5b1 from PSD2 to PSD4 because of ATN-161’s short
half-life (3.5-5 hours). Finally, we used a three-dose administration strategy where
ATN-161 was administered immediately at reperfusion, PSD1, and PSD2. This
dosing paradigm resulted in data that was consistent and effective.

We moved forward using the three-dose paradigm of ATN-161 at 1 mg/kg and
found that mice treated with ATN-161 experienced significantly reduced infarct
volumes (by ~50%) in both TTC images and the clinically relevant T2-weighted
MRI when compared to Vehicle treated controls. Cerebral edema was also
reduced on ADC MRI scans, a major cause of mortality following ischemic stroke
(11). To determine the extent of functional recovery, we used a novel 11-point
Neuroscore that was developed in our laboratory and is based off the clinically
applied modified Rankin Score. ATN-161 administration revealed a decrease in
dysfunction (lower numbers on the Neuroscore) at PSD3. Intriguingly, when we
compared the Neuroscore results at baseline, PSD1, and PSD3, we found
statistical improvement only at PSD3 following all three injections of ATN-161. This,
in addition to the inconsistent infarct volume results with a one dose and two dose
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administrations, implies a therapeutic effect where all three injections are required
to effectively inhibit the upregulation of integrin a5b1.

With our first hypothesis proven correct, we then moved to our second hypothesis:
post-stroke BBB permeability is reduced following ATN-161 administration. First,
we determined the extent of BBB dysfunction using the presence of IgG, a 150kDa
protein, in the brain parenchyma of perfused tissue. IgG detection is a commonly
used approach to assay BBB permeability in vivo as it is too large to pass through
the BBB under normal circumstances, but will be found in cerebral parenchyma
upon BBB disruption. Consistent with our discovery in a5 KO mice (65), ATN-161
treated mice showed a significant reduction in BBB permeability (less IgG in
cerebral parenchyma) when compared to the Vehicle treated controls. Next, we
wanted to further examine the endothelial and basement membrane stability by
looking at additional cerebrovascular elements related to stability. We found ATN161 treated mice expressed similar levels of the basement membrane protein
collagen IV, and extracellular matrix proteinase MMP-9, as compared to sham
mice. Vehicle treated mice, on the other hand, showed significant increases in
MMP-9 and decreased collagen IV, suggesting a dysfunctional basement
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membrane, all of which is absent in ATN-161 treated mice. Furthermore, ATN-161
stabilized the TJ protein, claudin-5 in the ischemic core as compared to Vehicle
treated mice. Increased claudin-5 is associated with less paracellular permeability,
though

function

of

claudin-5

(extracellular

localization

and

tyrosine

phosphorylation) has not been determined following ATN-161. Collectively, these
results show that ATN-161 treated mice have stable cerebrovascular structures
and thus, a less permeable BBB following experimental ischemic stroke.

Furthermore, it is also important to note that the extent of BBB permeability is not
only due to cerebrovascular stability and TJ expression/function, but it is also due
to the increase in inflammation. As described in Chapter 3, infiltrating leukocytes
occur during occlusion and continue long after reperfusion, exacerbating the space
between endothelial cells, edema (swelling), and expansion of brain damage.
Previous studies have shown the inability of integrin a5b1 inhibited leukocytes to
migrate, highlighting a potential role in post-stroke pathophysiology (261-262). We
used a pan-leukocyte marker, CD45+, on perfused tissue, and unsurprisingly
found ATN-161 administration resulted in reduced CD45+ cells when compared to
Vehicle controls. Because of saline perfusion, the amount of recruiting and rolling
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leukocytes are limited. Next, we determined a decrease in the transcription of the
IL-1b cytokine. We attributed this to an indirect product of reduced infiltration
because leukocytes are known to release a number of factors, including cytokines
and the earlier mentioned MMP-9. This introduced a conundrum, 1) was the
reduced infiltration of leukocytes due to reduced BBB permeability, 2) was ATN161 directly inhibiting leukocytic a5b1 and preventing migration, thus reducing
BBB dysfunction, or 3) a combination of both possibilities.

Thus, we next investigated the ability of leukocytes to be recruited to the site of
injury through the broad leukocyte recruiting chemokine, CXCL12. The presence
of CXCL12 is proven to reduce leukocytic infiltration following chronic hypoxia and
inflammatory autoimmune disease (277). As all experiments leading to this point
suggest a role for activate integrin a5b1 in promoting leukocytic infiltration, we
unsurprisingly found increased CXCL12 transcription under ATN-161 treatment.

Collectively, we found the inhibition of integrin a5b1 via ATN-161 following
experimental ischemic stroke reduced dysfunction and infarct volumes through
reduction of BBB permeability with interference in two different mechanisms,
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inflammation and tight junction protein expression. Thus, ATN-161 could be a new
therapeutic treatment for those experiencing reperfusion following experimental
stroke. Furthermore, these results show a post-stroke inflammatory and BBB
function role mediated by integrin a5b1. These are summarized in Figure 5.2.

Experimental caveats and limitations
The distal transient occlusion model used in all experiments, tandem/transient
CCA/MCA occlusion model, is a clinically relevant experimental model exhibiting
limited mortality (~5% in our laboratory, 65). The injury involves occluding the M2
branch of the MCA, resulting in an injury limited to the cortex. All animals
undergoing this surgery were exposed to similar amounts of anesthesia,
experimental procedure, occlusion period, and recovery time. Even with the
benefits of the model, there are still some caveats that need to be addressed. Most
notably, though all animals are genetically identical, differences in collateral
vasculature, the surrounding, supporting vasculature, can vary greatly. Clinically,
plasticity and damage has been associated with increased vasculature (294-295).
Thus, in a pre-clinical setting, the mouse cerebrovasculature could affect stroke
size and variance, independent of the model and treatment.
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Figure 5.2: A visual overview of integrin a5b1’s mechanism following experimental
stroke.
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We also focused on a limited time point, PSD3, when determining efficacy of ATN161 treatment as well as integrin a5b1 localization. As previously mentioned, the
PSD3 time point in our model represents the point of complete resolution of the
core into the peri-infarct. Thus, by analyzing our outcomes at PSD3, we ultimately
determined the ability of ATN-161 to prevent the expansion of the core into the
peri-infarct region, reminiscent of human ischemic stroke. However, this acute time
point misses the effect on delayed mechanisms, particularly angiogenesis, as
integrin a5b1 is the main promoter. This will be discussed in further detail in the
future directions section below.

In addition to the resulting stroke volume, our surgical outcomes affect the
behavioral performance and tests chosen. Because these are small, cortical
infarcts, mice will generally experience rear limb weakness and loss of sensation,
though fore paw and ocular involvement can occur. The 11-point Neuroscore exam
is more sensitive than other available behavioral tests such as open field and
rotarod, although the sensitivity is not enough to overcome the small cerebral injury,
introducing an unanticipated ceiling effect evident by a return to sham functional
levels on PSD7 and PSD14.
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The therapeutic we chose to inhibit integrin a5b1 was the small peptide, ATN-161.
Though it is advertised as a specific integrin a5b1 inhibitor, some binding to
integrin avb3 and a6b1 has been reported (156). Though potentially significant,
we determined not to pursue the potential effects of inhibition of these other
integrins in addition to integrin a5b1, as their expression is limited after stroke as
compared to integrin a5b1 (see Chapter 1 for more details). Furthermore, the more
chronically elevated integrin avb3 has been shown to increase integrin a5b1’s
affinity to fibronectin through cross-talk. Thus, inhibition of both a5b1 and avb3
integrins may ultimately be beneficial in increasing the efficacy of ATN-161 in
ischemic stroke.

With the addition of repeated dosing, we encountered a new limitation of our model.
Because of the vascular nature of integrin a5b1, we initially used the vascular
approach for ATN-161 administration through IV injections. Because integrin a5b1
is located luminally and in direct contact with the blood and IV drug administrations
are the most commonly used in the clinic. IV injections in mice are generally given
using the tail vein. Repeated injections, especially over consecutive days cause
scarring and deterioration of the tails, reducing the success of subsequent IV
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injections. In fact, successful injections were reduced to 20% from PSD1 to PSD2,
resulting in exclusion of mice. Though the three dose animals experienced ATN161 efficacy, the exceptionally low animal numbers were expensive and
statistically limiting. In fact, experiments were required to be high powered to
achieve a minimum of n=3 per treatment group. Thus, we turned our attention to
another mode of injection, IP, to reduce animal experimental loss while still
receiving benefit. Though, IP injections are less direct and result in delayed
vascular uptake from the abdomen (297), they are eventually absorbed by
surrounding vasculature. This potentially reduces the amount of drug entering the
vasculature, thus reducing the concentration in blood. Importantly, IP
administration of ATN-161 was successful, and mice still experienced benefits,
though not to the significance of IV injections.

Future Directions
Collectively, our results indicate that ATN-161 is safe and effective in treating
ischemic stroke in a clinically relevant dosing paradigm and experimental model.
However, it would be irresponsible to ignore the collective failures of clinical trials
for ischemic stroke, none the less the disappointment of ATN-161 in cancer clinical
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trials. Thus, future experiments are needed to further investigate the role of integrin
a5b1 and ATN-161 in ischemic stroke before an attempt at clinical translation is
pursued.

Though our previous results suggest an endothelial integrin a5b1 dominant
pathway (in Tie2Cre a5 KO mice), our results in Chapter 4 indicate a role for
integrin a5b1 in the post-stroke inflammatory cascade. This is further supported
by previous research on integrin a5b1’s role in cell migration under flow conditions
(reviewed in Chapter 3). Thus, we need to determine the effect of inflammation
under integrin a5b1 control on a cellular level through the effect of ATN-161 on
migrating cells. To test this, we will initially isolate leukocytes from bone marrow
from mice for culture. As described previously, we will administer ATN-161
following either oxygen-glucose deprivation or TNF-a administration to test both
conditions found following reperfusion in ischemic stroke. Based on the literature,
we expect ATN-161 treated cells to exhibit less migration than their control cells.

Another potential avenue is to ablate infiltrating neutrophils (the first infiltrating cells
as discussed in Chapter 3) using a Ly6G antibody prior to experimental ischemic.
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The Ly6G antibody has been shown to prohibit neutrophil production 2-3 days
following injection (298-299). This time frame is consistent with the resolution of
our model, thus allowing us to study the effects of endothelial integrin a5b1
independently. The observed strokes will be smaller, but we will be able to observe
the effects of inflammation and BBB permeability following ATN-161 administration
in the same dosing paradigm discussed in Chapter 4. Following neutrophil ablation
and ATN-161 administration, we hypothesize that endothelial integrin a5b1 is the
main promoter of BBB permeability independent of inflammation, so claudin-5,
MMP-9 and collagen IV will be unaffected. Furthermore, we can observe leukocyte
migration in a5 KO mice using the CD45+ antibody in perfused (infiltrating cells)
and non-perfused (leukocytic rolling) tissue to determine if endothelial integrin
a5b1 are responsible for leukocyte infiltration.

Though our previous results suggest an endothelial integrin a5b1 dominant
pathway (in Tie2Cre a5 KO mice), our results in Chapter 4 indicate a role for
integrin a5b1 in the post-stroke inflammatory cascade. This is further supported
by previous research on integrin a5b1’s role in cell migration under flow conditions
(reviewed in Chapter 3). Thus, we need to determine the effect of inflammation
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under integrin a5b1 control on a cellular level through the effect of ATN-161 on
migrating cells. To test this, we will initially isolate leukocytes from bone marrow
from mice for culture. As described previously, we will administer ATN-161
following either oxygen-glucose deprivation or TNF-a administration to test both
conditions found following reperfusion in ischemic stroke. Based on the literature,
we expect ATN-161 treated cells to exhibit less migration than their control cells.

Next, we need to determine the mechanism of action for clauidn-5 using several in
vitro experiments. Though the exact mechanism through which integrin a5b1 and
claudin-5 expression are tied has not yet been determined, there are two
possibilities. The first, as shown in Figure 5.2, shows fibronectin bound integrin
a5b1 inhibiting PKA, a protein kinase, and GDI, a GDP inhibitor regulating Rho
GTPases. As a result, cytoskeleton regulators, RhoA and ROCK1, are increased,
promoting phosphorylation and inactivation of claudin-5 (as described in our NIH
RO1). While this may apply, current results show a decrease in claudin-5
transcription (Chapter 4) and inability of integrin a5b1 to bind fibronectin following
stroke (Chapter 2). Another possibility is activation of integrin a5b1 acting as an
inhibitor of the canonical Wnt/b-cat pathway (Figure 5.4). This pathway seems
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more likely, because we see a loss in transcription of claudin-5. Here, activated
integrin a5b1 acts as an inhibitor of the canonical Wnt/b-cat pathway. Upon
inhibition, b-catenin is decreased and does not translocate to the nucleus,
preventing transcription of target genes, such as claudin-5.

To test both pathways, we are currently using cultured brain endothelial cells to
test for the cell signaling pathway upon activation following oxygen-glucose
deprivation (OGD, also referred to as “stroke in a dish”) and after an inflammatory
state (i.e. adding the inflammatory cytokines TNF-a or IL-1b). Following ATN-161
administration and/or inhibitors based on the pathways in Figure 5.4 and 5.5, we
plan to quantify qPCR, western blot, and immunoprecipitation.

In Chapter 4, we focused only on the effects of removal of integrin a5b1 activity
via ATN-161. It is important to note that ATN-161, though advertised as an inhibitor
of integrin a5b1, also possesses some specificity for integrin avb3 and a6b1 (296).
As discussed earlier in this chapter, both integrin a6b1 and avb3 are unlikely
targets, however the full extent of their role in ischemic stroke has not been
determined. A few additional experiments need to be performed to determine the
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Figure 5.3: Representative diagram of integrin a5b1 working through PKA and
ROCK1 to inactivate claudin-5 with phosphorylation.
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Figure 5.4: Representative diagram of integrin a5b1 working through the
canonical Wnt pathway to prevent claudin-5 translocation.
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specificity of ATN-161. First, we can determine binding of ATN-161 using
biotinylation techniques and co-label with integrins a5b1, avb3, and a6b1.

Previous studies with ATN-453, a biotinylated version of ATN-161 that is no longer
available, have shown a high preference for integrin a5b1 binding over avb3 and
a6b1 when integrin a5b1 is expressed at high levels (156). As this is similar to
what is seen in ischemic stroke, we do not expect to see different results.

In addition to the specificity of ATN-161, investigation into chronic mechanisms,
such as angiogenesis, has not yet been determined. Angiogenesis is a delayed
process, where new vessels are not seen until PSD3 and continually increase
through PSD14. However, the initiation of cerebrovascular remodeling is observed
within hours following reperfusion (292). Mainly, the role of angiogenesis is to
restore circulation to areas of damage from ischemia, as well as to support other
aspects of neurorepair (i.e. neurogenesis) and are viewed as a high priority for
post stroke recovery (300). As a main promoter, acute inhibition of integrin a5b1
may also negatively impact plasticity and neurorestoration. We hypothesize that
the process of angiogenesis is largely not impacted, though delayed. Additionally,

22

because there is less damage with integrin a5b1 inhibition, there is also less repair
that needs to occur. Thus, even if delayed, angiogenesis process will be less
essential for repair following the stroke. Integrin a5b1 expression continually
increases through PSD7 before decreasing upon angiogenesis at PSD14. This,
combined with the short half-life of ATN-161 and the short period of administration
(up to 48 hours post-stroke), suggests a reduction in acute cerebrovascular
remodeling, but left with the capabilities for chronic remodeling. Additional support
for this theory is shown by no difference in function on PSD14 in ATN-161 treated
mice compared to controls (Figure 5.5).

Finally, it appears that integrin a5b1 may have a more diverse role in different
diseases. Increases in integrin a5b1 have been observed in animal models of
Moya Moya (301) and vascular dementia. Both diseases are a result of faulty
cerebrovasculature and angiogenesis. Thus, there are current investigations into
administrating ATN-161 prior to disease onset.
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Improved Function

6

Conclusion
Though integrin a5b1 has been historically studied as a pro-angiogenic endothelial
integrin. In this discussion, we described the effects of integrin a5b1 on post-stroke
inflammation and cerebrovascular stability following ischemic stroke. With the
administration of the small peptide, ATN-161, these results are reversed,
decreasing infarct volumes and improving outcomes. Thus, investigation into
targeting integrin a5b1 with ATN-161 in the clinical treatment of ischemic stroke
merits additional investigation.
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Appendix A: List of Abbreviations
Abbreviation

Definition

a5 KO

Endothelial specific a5 knockout mice

BBB

Blood-brain barrier

CCA

Common carotid artery

Core

Initial ischemic damage

ECM

Extracellular matrix

GPCR

G-protein coupled receptors

ICAM

Intracellular adhesion molecules

IP

Intraperitoneal

IV

Intravenous

JAM

Junctional adhesion molecules

MCA

Middle cerebral artery

MCAO

Middle cerebral artery occlusion

MMP

Matrix metalloproteinase

OGD

Oxygen-glucose deprivation

Peri-infarct

At risk tissue

PHSRN

Proline-Histidine-Serine-Arginine-Asparganine

PMN

Polymorphonuclear lymphocytes

PSD

Post-stroke day

RGD

Arginine-Glycine-Aspartate

t-PA

Tissue plasminogen activator

TJ

Tight junction

VCAM

Vascular cell adhesion molecule

VEGF

Vascular endothelial growth factor

VEGFR-1

Vascular endothelial growth factor receptor-1

ZO-1

Zonna occludin-1

128

Appendix B: Neurological Severity Score

129

References

1. Benjamin EJ, MJ B, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart
Disease and Stroke Statistics—2017 Update: A Report From the American
Heart Association. Stroke. 2017;137:1-459.
2. Golestanian E, Liou JI and Smith MA. Long-term survival in older critically
ill patients with acute ischemic stroke. Crit Care Med. 2009;37:3107-3113.
3. Rai AT, Seldon AE, Boo S, Link PS, Domico JR, Tarabishy AR, et al. A
population-based incidence of acute large vessel occlusions and
thrombectomy eligible patients indicates significant potential for growth of
endovascular stroke therapy in the USA. J Neurointerv Surg. 2017;9:722726.
4. Rao NM, Levine SR, Gornbein JA and Saver JL. Defining clinically relevant
cerebral hemorrhage after thrombolytic therapy for stroke: analysis of the
National Institute of Neurological Disorders and Stroke tissue-type
plasminogen activator trials. Stroke. 2014;45:2728-2733.
5. Duz B, Oztas E, Erginay T, Erdogan E and Gonul E. The effect of moderate
hypothermia in acute ischemic stroke on pericyte migration: an
ultrastructural study. Cryobiology. 2007;55:279-284.
6. Feign VL, Norrving B, George MG, Foltz JL, Roth GA and Mensah GA.
Prevention of stroke: a strategic global imperative. Nature Reviews
Neurology. 2016;12:501-512.
7. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, et
al. Global burden of stroke and risk factors in 188 countries, during 1990–
2013: a systematic analysis for the Global Burden of Disease Study 2013.
The Lancet Neurology. 2016;15:913-924.
8. Johnson BH, Bonafede MM and Watson C. Short- and longer-term healthcare resource utilization and costs associated with acute ischemic stroke.
Clinicoecon Outcomes Res. 2016;8:53-61.
9. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD,
Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular
diseases: lifetime risks, healthy life-years lost, and age-specific
associations in 1·25 million people. The Lancet. 2014;383:1899-1911.
10. Rothwell P, Coull A, Silver L, Fairhead J, Giles M, Lovelock C, et al.
Population based study of event rate, incidence, case, fatality, and mortality
for all acute vascular events in all arterial territories (Oxford Vascular Study).
Lancet. 2005;366:1773-1783.
130

11. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ,
et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the
American Heart Association. Circulation. 2016;133:e38-360.
12. Dirnagl U, Iadecola C and Moskowitz MA. Pathobiology of ischemic stroke:
an integrated view. Trends in Neuroscience. 1999;22:391-397.
13. Yang JT, Rayburn H and Hynes RO. Embryonic mesodermal defects in
alpha 5 integrin-deficient mice. Development. 1993;119:1093-1105.
14. Bounds JV, Wiebers DO, Whisnant JP and Okazaki H. Mechanisms and
Timing of Deaths from Cerebral Infarction. Stroke. 1981;12:474-477.
15. Devakis A, Toni D, Iweins F, Lesaffre E, Bastianello S and Castillo J.
Neurological Deterioration in Acute Ischemic Stroke: Potential Predictors
and Associated Factors in the European Cooperative Acute Stroke Study
(ECASS) I. Stroke. 1999;30:1631-2636.
16. Sandoval KE and Witt KA. Blood-brain barrier tight junction permeability and
ischemic stroke. Neurobiology of Disease. 2008;32:200-219.
17. Heo JH, Han SW and Lee SK. Free radicals as triggers of brain edema
formation after stroke. Free Radic Biol Med. 2005;39:51-70.
18. Schlaug G, Siewart B, Benfield A, Edelman RR and Warach S. Time course
of the apparent diffusion coefficient (ADC) abnormality in human stroke.
Neurology. 1996;49:113-119.
19. Abo-Ramadan U, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E,
Pedrono E, et al. Post-ischemic leakiness of the blood-brain barrier: a
quantitative and systematic assessment by Patlak plots. Exp Neurol.
2009;219:328-333.
20. Maki T, Hayakawa K, Pham L-DD, Xing C, Lo EH and Arai K. Biphasic
mechanisms of neurovascular unit injury and protection in CNS disease.
CNS & Neurological Disorders Drug Targets. 2013;12:302-315.
21. Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E,
et al. The blood-brain barrier is continuously open for several weeks
following transient focal cerebral ischemia. Neuroscience. 2008;153:175181.
22. Witt KA, Mark KS, Sandoval K and Davis TP. Reoxygenation stress on
blood brain barrier paracellular permeability and edema in the rat.
Microvascular Research. 2008;75:91-96.
23. Kwon I, Kim EH, del Zoppo GJ and Heo JH. Ultrastructural and Temporal
Changes of the Microvascular Basement Membrane and Astrocyte
131

Interface Following Focal Cerebral Ischemia. Journal of Neuroscience
Research. 2009;87:668-676.
24. Faraci FM. Protecting against vascular disease in brain. Am J Physiol Heart
Circ Physiol. 2011;300:H1566-1582.
25. Flammer AJ and Luscher TF. Three decades of endothelium research: from
the detection of nitric oxide to the everyday implementation of endothelial
function measurements in cardiovascular diseases. Swiss Med Wkly.
2010;140:w13122.
26. Fogal B and Pober JS. Vascular Endothelial Cells as Immunological Targets
in Atheroscleroisis. Inflammation and Atherlosclerosis. 2012.
27. Vanhoutte PM, Shimokawa H, Feletou M and Tang EH. Endothelial
dysfunction and vascular disease - a 30th anniversary update. Acta Physiol
(Oxf). 2017;219:22-96.
28. Xiao F. Bench to bedside- brain edema and cerebral resuscitation the
present and future. Academic Emergency Medicine. 2002;9:933-946.
29. Takada Y, Ye X and Simon S. The integrins. Genome Biol. 2007;8:215.
30. Davis MJ, Wu X, Nurkiewicz J, Davis GE, Hill MA and Meininger GA.
Integrins and mechanotransduction of the vascular myogenic response.
American Journal of Physiology-Heart and Circulatory Physiology.
2001;280:H1427-H1433.
31. Wang N, Butler JP and Ingber DE. Mechanotransduction across the cell
surface and through the cytoskeleton. Science. 1993;260:1124-1127.
32. Wu X and Reddy DS. Integrins as receptor targets for neurological
disorders. Pharmacol Ther. 2012;134:68-81.
33. Clark AW and Brugge JS. Integrins and signal transuction pathways: the
road taken. Science. 1995;268:233-239.
34. Cox D, Brennan M and Moran N. Integrins as therapeutic targets: lessons
and opportunities. Nature Reviews Drug Discovery. 2010;9:804-820.
35. Hynes RO. Integrins: Versatility, modulation, and signaling in cell adhesion
Cell. 1992;69:11-25.
36. Hynes RO. Integrins: Bidrirectional, allosteric signaling machines. Cell.
2002;110:673-687.
37. Kim C, Ye F and Ginsberg MH. Regulation of integrin activation. Annu Rev
Cell Dev Biol. 2011;27:321-345.
38. Yamada KM and Miyamoto S. Integrin transmembrane signaling and
cytoskeleton control. Current Opinion in Cell Biology. 1995;7:681-689.
132

39. Baeten KM and Akassoglou K. Extracellular Matrix and Matrix Receptors in
Blood-Brain Barrier Formation and Stroke. Developmental Neurobiology.
2011;71:1018-1039.
40. Eliceiri BP and Cheresh DA. Adhesion events in angiogenesis. Current
Opinion in Cell Biology. 2001;13:563-568.
41. Okada Y, Copeland BR, Hamann GF, Koziol JA, Cheresh DA and del Zoppo
GJ. Integrin alphavbeta3 is expressed in selected microvessels after focal
cerebral ischemia. American Journal of Pathology. 1996;149:37-44.
42. Wei L, Erinjeri JP, M. RC and Woosley TA. Collateral Growth and
Angiogenesis Around Cortical Stroke. Stroke. 2001;32:2179-2184.
43. De Arcangelis A and Georges-Labouesse E. Integrin and ECM functions:
roles in vertebrate development. Trends in Genetics. 2000;16:389-395.
44. McCarty JH, Lacy-Hulbert A, Charest A, Bronson RT, Crowley D, Housman
D, et al. Selective ablation of alphav integrins in the central nervous system
leads to cerebral hemorrhage, seizures, axonal degeneration and
premature death. Development. 2005;132:165-176.
45. Abumiya T, Lucero J, Heo JH, Tagaya M, Koziol JA, Copeland B, et al.
Activated microvessels express vascular endothelial growth factor and
integrin avb3 during focal cerebral ischemia. Journal of Cerebral Blood Flow
and Metabolism. 1999;19:1038-1050.
46. Huang Q, Chen B, Wang F, Huang H, Milner R and Li L. The temporal
expression patterns of fibronectin and its receptors-alpha5beta1 and
alphavbeta3 integrins on blood vessels after cerebral ischemia. Restor
Neurol Neurosci. 2015;33:493-507.
47. Costell M, Gustafsson E, Aszodi A, Morgelin M, Bloch W, Hunziker E, et al.
Perlecan maintains the integrity of cartilage and some basement
membranes. Journal of Cell Biology. 1999;147:1109-1122.
48. Plate KH, Beck H, Danner S, Allegrini PR and Wiessner C. Cell type specific
upregulation of vascular endothelial growth factor in an MCA-occlusion
model of cerebral infarct. Journal of Neuropathology and Experimental
Neurology. 1999;58:654-666.
49. Alghisi GC, Ponsonnet L and Ruegg C. The integrin antagonist cilengitide
activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions
and enhances permeability in endothelial cells. PLoS One. 2009;4:e4449.
50. Fischer S, Wiesnet M, Marti HH, Renz D and Schaper W. Simultaneous
activation of several second messengers in hypoxia-induced
133

hyperpermeability of brain derived endothelial cells. J Cell Physiol.
2004;198:359-369.
51. Garcia JH, Liu K-F, Yoshida Y, Chen S and Lian J. Brain microvesselsfactors altering their patency after the occlusion of a middle cerebral artery
(Wistar rat). American Journal of Pathology. 1994;145:728-740.
52. Orecchia A, Lacal PM, Schietroma C, Morea V, Zambruno G and Failla CM.
Vascular endothelial growth factor receptor-1 is deposited in the
extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta
1 integrin. J Cell Sci. 2003;116:3479-3489.
53. Shen W, Li S, Chung SH, Zhu L, Stayt J, Su T, et al. Tyrosine
phosphorylation of VE-cadherin and claudin-5 is associated with TGFbeta1-induced permeability of centrally derived vascular endothelium. Eur
J Cell Biol. 2011;90:323-332.
54. Wang W, Dentler WL and Borchardt RT. VEGF increases BMEC monolayer
permeability by affecting occludin expression and tight junction assembly.
American Journal of Physiology-Heart and Circulatory Physiology.
2001;280:H434-H440.
55. Shimamura N, Matchett G, Yatsushige H, Calvert JW, Ohkuma H and
Zhang J. Inhibition of integrin alphavbeta3 ameliorates focal cerebral
ischemic damage in the rat middle cerebral artery occlusion model. Stroke.
2006;37:1902-1909.
56. Shimamura N, Matchett G, Solaroglu I, Tsubokawa T, Ohkuma H and
Zhang J. Inhibition of integrin alphavbeta3 reduces blood-brain barrier
breakdown in focal ischemia in rats. Journal of Neuroscience Research.
2006;84:1837-1847.
57. Schaffner F, Ray AM and Dontenwill M. Integrin alpha5beta1, the
Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors.
Cancers (Basel). 2013;5:27-47.
58. Bharadwaj M, Strohmeyer N, Colo GP, Helenius J, Beerenwinkel N, Schiller
HB, et al. alphaV-class integrins exert dual roles on alpha5beta1 integrins
to strengthen adhesion to fibronectin. Nat Commun. 2017;8:14348.
59. George EL, Georges-Labouesse EN, Patel-King RS, Rayburn H and Hynes
RO. Defects in mesoderm, neural tube and vascular development in mouse
embryos lacking fibronectin. Development. 1993;119:1079-1091.

134

60. Goh KL, Yang JT and Hynes RO. Mesodermal defects and cranial neural
crest apoptosis in alpha5 integrin-null embryos. Development.
1997;124:4309-4319.
61. Yang JT, Rayburn H and Hynes RO. Embryonic mesodermal defects in
alpha 5 integrin-deficient mice. Development. 1993;119:1093-1105.
62. Li L, Welser JV and Milner R. Absence of the alpha v beta 3 integrin dictates
the time-course of angiogenesis in the hypoxic central nervous system:
accelerated endothelial proliferation correlates with compensatory
increases in alpha 5 beta 1 integrin expression. J Cereb Blood Flow Metab.
2010;30:1031-1043.
63. Li L, Welser-Alves J, van der Flier A, Boroujerdi A, Hynes RO and Milner R.
An angiogenic role for the alpha5beta1 integrin in promoting endothelial cell
proliferation during cerebral hypoxia. Exp Neurol. 2012;237:46-54.
64. Orecchia A, Lacal PM, Schachtrup C, Morea V, Zambruno G and Failla CM.
Vascular Endothelial Growth Factor Upregulates the Expression of Matrix
Metalloproteinases in Vascular Smooth Muscle Cells Role of flt-1. Journal
of Cell Science. 2003;116:3479-3489.
65. Roberts J, de Hoog L and Bix GJ. Mice deficient in endothelial alpha5
integrin are profoundly resistant to experimental ischemic stroke. J Cereb
Blood Flow Metab. 2015;37:85-96.
66. Milner R. Developmental Regulation of β1 Integrins during Angiogenesis in
the Central Nervous System. Molecular and Cellular Neuroscience.
2002;20:616-626.
67. Milner R and Campbell IL. Increased expression of the β4 and α5 integrin
subunits in cerebral blood vessels of transgenic mice chronically producing
the pro-inflammatory cytokines IL-6 or IFN-α in the central nervous system.
Molecular Cell Neurosceince. 2006;33:429-440.
68. Wagner S, Tagaya M, Koziol JA, Quaranta V and del Zoppo GJ. Rapid
disruption of an astrocyte interaction with the extracellular matrix mediated
by integrin alpha 6 beta 4 during focal cerebral ischemia/reperfusion.
Stroke. 1997;28:858-865.
69. Tagaya M, Haring H-P, Stuiver I, Wagner S, Abumiya T, Lucero J, et al.
Rapid loss of microvascular integrin expression during focal brain ischemia
reflects neuron injury. Journal of Cerebral Blood Flow and Metabolism.
2001;21:835-846.

135

70. Osada T, Gu YH, Kanazawa M, Tsubota Y, Hawkins BT, Spatz M, et al.
Interendothelial claudin-5 expression depends on cerebral endothelial cellmatrix adhesion by beta(1)-integrins. J Cereb Blood Flow Metab.
2011;31:1972-1985.
71. Kular JK, Basu S and Sharma RI. The extracellular matrix: Structure,
composition, age-related differences, tools for analysis and applications for
tissue engineering. J Tissue Eng. 2014;5:2041731414557112.
72. Novak U and Kaye AH. Extracellular matrix and the brain: components and
function. Journal of Clinical Neuroscience. 2000;7:280-290.
73. Barros CS, Franco SJ and Muller U. Extracellular matrix: functions in the
nervous system. Cold Spring Harb Perspect Biol. 2011;3:a005108.
74. Kim SH, Turnbull J and Guimond S. Extracellular matrix and cell signalling:
the dynamic cooperation of integrin, proteoglycan and growth factor
receptor. J Endocrinol. 2011;209:139-151.
75. Pankov R. Fibronectin at a glance. Journal of Cell Science. 2002;115:38613863.
76. To WS and Midwood KS. Plasma and cellular fibronectin: distinct and
independent functions during tissue repair. Fibrogenesis Tissue Repair.
2011;4:21.
77. Mongiat M, Andreuzzi E, Tarticchio G and Paulitti A. Extracellular Matrix, a
Hard Player in Angiogenesis. Int J Mol Sci. 2016;17(11):1882.
78. Nicosia RF, Bonanno E and Smith M. Fibronectin promotes the elongation
of microvessels during angiogenesis in vitro. Journal of Cell Physiology.
1993;154:654-661.
79. Sakai T, Johnson KJ, Murosono M, Sakai K, Magnuson MA, Wieloch T, et
al. Plasma fibronectin supports neuronal survival and reduces brain injury
following transient focal cerebral ischemia but is not essential for skinwound healing and hemostasis. Nature Medicine. 2001;7:324-330.
80. Wang Y, Reheman A, Spring CM, Kalantari J, Marshall AH, Wolberg AS, et
al. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin
Invest. 2014;124:4281-4293.
81. Li L, Liu F, Welser-Alves JV, McCullough LD and Milner R. Upregulation of
fibronectin and the alpha5beta1 and alphavbeta3 integrins on blood vessels
within the cerebral ischemic penumbra. Exp Neurol. 2012;233:283-291.
82. Tate CC, Garcia AJ and LaPlaca MC. Plasma fibronectin is neuroprotective
following traumatic brain injury. Exp Neurol. 2007;207:13-22.
136

83. Klein T and Bischoff R. Physiology and pathophysiology of matrix
metalloproteases. Amino Acids. 2011;41:271-290.
84. Wossener JF. Matrix metalloproteinases and their inhibitors in connective
tissue remodeling. Faseb Journal. 1991;5:2144-2154.
85. Clark AW, Krekoski CA, Bou S-S, Chapman KR and Edwards DR.
Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in
human brain after focal ischemia. Neuroscience Letters. 1997;238:53-56.
86. Lee CZ, Xue Z, Zhu Y, Yang GY and Young WL. Matrix metalloproteinase9 inhibition attenuates vascular endothelial growth factor-induced
intracerebral hemorrhage. Stroke. 2007;38:2563-2568.
87. McColl BW, Rothwell NJ and Allan SM. Systemic inflammation alters the
kinetics of cerebrovascular tight junction disruption after experimental
stroke in mice. J Neurosci. 2008;28:9451-9462.
88. Castellanos M, Leira R, Serena J, Blanco M, Pedraza S, Castillo J, et al.
Plasma
cellular-fibronectin
concentration
predicts
hemorrhagic
transformation after thrombolytic therapy in acute ischemic stroke. Stroke.
2004;35:1671-1676.
89. Castellanos M, Sobrino T, Millán M, García M, Arenillas J, Nombela F, et
al. Serum cellular fibronectin and matrix metalloproteinase-9 as screening
biomarkers for the prediction of parenchymal hematoma after thrombolytic
therapy in acute ischemic stroke: a multicenter confirmatory study. Stroke.
2007;38:1855-1859.
90. Colognato H and Yurchenco PD. Form and function: the laminin family of
heterotrimers. Developmental Dynamics. 2000;218:
91. Hallmann R, Horn N, Selg M, Wendler O, Pausch F and Sorokin LM.
Expression and function of laminins in the embryonic and mature
vasculature. Physiol Rev. 2005;85:979-1000.
92. Li S, Edgar D, Fassler R, Wadsworth W and Yurchenco PD. The role of
laminin in embryonic cell polarization and tissue organization.
Developmental Cell. 2003;4:613-624.
93. Miner JH and Yurchenco PD. Laminin functions in tissue morphogenesis.
Annu Rev Cell Dev Biol. 2004;20:255-284.
94. Yousif LF, Di Russo J and Sorokin L. Laminin isoforms in endothelial and
perivascular basement membranes. Cell Adh Migr. 2013;7:101-110.
95. Jucker M, Bialobok P, Kleinman HK, Walker LC, Hagg T and Ingram DK.
Laminin-like and laminin-binding protein-like immunoreactive astrocytes in
137

rat hippocampus after transient ischemia. Antibody to laminin-binding
protein is a sensitive marker of neural injury and degeneration. Annals of
the New York Academy of Science. 1993;28:245-252.
96. Sixt M, Engelhardt B, Pausch F, Hallmann R, Wendler O and Sorokin LM.
Endothelial cell laminin isoforms, laminins 8 and 10 play decisive roles in t
cell recruitment across the blood brain barrier in experimental autoimmune
encephalomyetis. Journal of Cell Biology. 2001;153:933-945.
97. Sorokin LM, Pausch F, Frieser M, Kroger S, Ohage E and Deutzmann R.
Developmental regulation of the laminin alpha5 chain suggests a role in
epithelial and endothelial cell maturation. Developmental Biology.
1997;189:285-300.
98. Yemisci M, Gursoy-Ozdemir Y, Vural A, Can A, Topalkara K and Dalkara T.
Pericyte contraction induced by oxidative-nitrative stress impairs capillary
reflow despite successful opening of an occluded cerebral artery. Nat Med.
2009;15:1031-1037.
99. Thyboll J, Kortesmaa J, Cao R, Soininen R, Wang L, Iivanainen A, et al.
Deletion of the Laminin 4 Chain Leads to Impaired Microvessel Maturation.
Molecular and Cellular Biology. 2002;22:1194-1202.
100.
Smyth N, Vatansever HS, Murray P, Meyer M, Frie C, Paulsson M,
et al. Absence of basement membranes after targeting the LAMC1 gene
results in embryonic lethality due to failure of endoderm differentiation.
Journal of Cell Biology. 1999;144:151-160.
101.
Chen ZL, Yao Y, Norris EH, Kruyer A, Jno-Charles O, Akhmerov A,
et al. Ablation of astrocytic laminin impairs vascular smooth muscle cell
function and leads to hemorrhagic stroke. J Cell Biol. 2013;202:381-395.
102.
Yao Y, Chen ZL, Norris EH and Strickland S. Astrocytic laminin
regulates pericyte differentiation and maintains blood brain barrier integrity.
Nat Commun. 2014;5:3413.
103.
Szabo A and Kalman M. Disappearance of the post-lesional laminin
immunopositivity of brain vessels is parallel with the formation of
gliovascular junctions and common basal lamina. Neuropathology and
Applied Neurobiology. 2004;30:169-177.
104.
Kangwantas K, Pinteaux E and Penny J. The extracellular matrix
protein laminin-10 promotes blood-brain barrier repair after hypoxia and
inflammation in vitro. J Neuroinflammation. 2016;13:25.

138

105.
Mettouchi A, Klein S, Guo W, Lago-Lopez M, Lemichez E, Westick
JK, et al. Integrin specific activation of rac controls progression through the
G(1) phase of the cell cycle. Molecular Cell. 2001;8:115-127.
106.
Pákáski M, Kása P, Joó F and Wolff JR. Cerebral endothelial cellderived laminin promotes the outgrowth of neurites in CNS neuronal
cultures. International Journal of Developmental Neuroscience.
1990;8:193-198.
107.
Fujioka T, Kaneko N, Ajioka I, Nakaguchi K, Omata T, Ohba H, et al.
Beta-1 integrin signaling promotes neuronal migration along vascular
scaffolds in the post-stroke brain. EBioMedicine. 2017;16:195-203.
108.
Knox SM and Whitelock JM. Perlecan: how does one molecule do
so many things? Cell Mol Life Sci. 2006;63:2435-2445.
109.
Melrose J, Roughley P, Knox S, Smith S, Lord M and Whitelock J.
The structure, location, and function of perlecan, a prominent pericellular
proteoglycan of fetal, postnatal, and mature hyaline cartilages. J Biol Chem.
2006;281:36905-36914.
110.
Whitelock JM, Melrose J and Iozzo RV. Diverse cell signaling events
modulated by perlecan. Biochemistry. 2008;47:11174-11183.
111.
Handler M, Yurchenco PD and Iozzo RV. Developmental expression
of perlecan during murine embryogenesis. Developtmental Dynamics.
1997;210:130-145.
112.
Ford-Perriss M, Turner K, Guimond S, Apedaile A, Haubeck HD,
Turnbull J, et al. Localisation of specific heparan sulfate proteoglycans
during the proliferative phase of brain development. Dev Dyn.
2003;227:170-184.
113.
Rodgers KD, Sasaki T, Aszodi A and Jacenko O. Reduced perlecan
in mice results in chondrodysplasia resembling Schwartz-Jampel
syndrome. Hum Mol Genet. 2007;16:515-528.
114.
Clarke DN, Al Ahmad A, Lee B, Parham C, Auckland L, Fertala A, et
al. Perlecan Domain V induces VEGf secretion in brain endothelial cells
through integrin alpha5beta1 and ERK-dependent signaling pathways.
PLoS One. 2012;7:e45257.
115.
Lee B, Clarke D, Al Ahmad A, Kahle M, Parham C, Auckland L, et al.
Perlecan domain V is neuroprotective and proangiogenic following ischemic
stroke in rodents. Journal of Clinical Neuroscience. 2011;121:3005-3023.
139

116.
Bix GJ, Gowing EK and Clarkson AN. Perlecan domain V is
neuroprotective and affords functional improvement in a photothrombotic
stroke model in young and aged mice. Transl Stroke Res. 2013;4:515-523.
117.
Patino M, Neiders M, Andreana S, Noble B and Cohen RE. Collagen:
An Overview. Implant Denistry. 2002;11:280-284.
118.
Terni E, Giannini N, Brondi M, Montano V, Bonuccelli U and
Mancuso M. Genetics of ischaemic stroke in young adults. BBA Clin.
2015;3:96-106.
119.
Hamann GF, Liebetrau M, Martens H, Burggraf D, Kloss C,
Bultemeier G, et al. Microvascular basal lamina injury after experimental
focal cerebral ischemia and reperfusion in rat. Journal of Cerebral Blood
Flow and Metabolism. 2002;22:526-533.
120.
Hartig W, Mages B, Aleithe S, Nitzsche B, Altmann S, Barthel H, et
al. Damaged Neocortical Perineuronal Nets Due to Experimental Focal
Cerebral Ischemia in Mice, Rats and Sheep. Front Integr Neurosci.
2017;11:15.
121.
Krueger M, Bechmann I, Immig K, Reichenbach A, Hartig W and
Michalski D. Blood-brain barrier breakdown involves four distinct stages of
vascular damage in various models of experimental focal cerebral ischemia.
J Cereb Blood Flow Metab. 2015;35:292-303.
122.
Haley MJ and Lawrence CB. The blood-brain barrier after stroke:
Structural studies and the role of transcytotic vesicles. J Cereb Blood Flow
Metab. 2017;37:456-470.
123.
Knowland D, Arac A, Sekiguchi KJ, Hsu M, Lutz SE, Perrino J, et al.
Stepwise recruitment of transcellular and paracellular pathways underlies
blood-brain barrier breakdown in stroke. Neuron. 2014;82:603-617.
124.
Krueger M, Hartig W, Reichenbach A, Bechmann I and Michalski D.
Blood-brain barrier breakdown after embolic stroke in rats occurs without
ultrastructural evidence for disrupting tight junctions. PLoS One.
2013;8:e56419.
125.
Ahsan MS, Yamazaki M, Maruyama S, Kobayashi T, Ida-Yonemochi
H, Hasegawa M, et al. Differential expression of perlecan receptors, alphadystroglycan and integrin beta1, before and after invasion of oral squamous
cell carcinoma. J Oral Pathol Med. 2011;40:552-559.
126.
Alvarez JI, Katayama T and Prat A. Glial influence on the blood brain
barrier. Glia. 2013;61:1939-1958.
140

127.
Hamby ME and Sofroniew MV. Reactive astrocytes as therapeutic
targets for CNS disorders. The American Society for Experimental
NeuroTherapeutics. 2010;7:494-506.
128.
Maragakis NJ and Rothstein JD. Mechanisms of Disease: astrocytes
in neurodegenerative disease. Nature Clinical Practice Neurology.
2006;2:679-689.
129.
Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE and Searson
PC. The blood-brain barrier: an engineering perspective. Front Neuroeng.
2013;6:7.
130.
Zonta M, Angulo MC, Gobbo S, Rosengarten B, Hossmann KA,
Pozzan T, et al. Neuron-to-astrocyte signaling is central to the dynamic
control of brain microcirculation. Nat Neurosci. 2003;6:43-50.
131.
Tagaya M, Liu KF, Copeland B, Seiffert D, Engler R, Garcia JH, et
al. DNA Scission After Focal Brain Ischemia : Temporal Differences in Two
Species. Stroke. 1997;28:1245-1254.
132.
Lutz SE, Zhao Y, Gulinello M, Lee SC, Raine CS and Brosnan CF.
Deletion of astrocyte connexins 43 and 30 leads to a dysmyelinating
phenotype and hippocampal CA1 vacuolation. J Neurosci. 2009;29:77437752.
133.
Bergers G and Song S. The role of pericytes in blood-vessel
formation and maintenance. Neuro Oncol. 2005;7:452-464.
134.
Winkler EA, Bell RD and Zlokovic BV. Central nervous system
pericytes in health and disease. Nat Neurosci. 2011;14:1398-1405.
135.
Armulik A, Genove G, Mae M, Nisancioglu MH, Wallgard E, Niaudet
C, et al. Pericytes regulate the blood-brain barrier. Nature. 2010;468:557561.
136.
Bai Y, Zhu X, Chao J, Zhang Y, Qian C, Li P, et al. Pericytes
contribute to the disruption of the cerebral endothelial barrier via increasing
VEGF expression: implications for stroke. PLoS One. 2015;10:e0124362.
137.
Bell RD, Winkler EA, Sagare AP, Singh I, LaRue B, Deane R, et al.
Pericytes control key neurovascular functions and neuronal phenotype in
the adult brain and during brain aging. Neuron. 2010;68:409-427.
138.
Fukuda S, Fini CA, Mabuchi T, Koziol JA, Eggleston LL, Jr. and del
Zoppo GJ. Focal cerebral ischemia induces active proteases that degrade
microvascular matrix. Stroke. 2004;35:998-1004.

141

139.
Gonul E, Duz B, Kahraman S, Kayali H, Kubar A and Timurkaynak
E. Early pericyte response to brain hypoxia in cats: an ultrastructural study.
Microvasc Res. 2002;64:116-119.
140.
Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S,
Tanaka N, et al. Vascular endothelial growth factor acts as a pericyte
mitogen under hypoxic conditions. Laboratory Investigation. 1999;79:501509.
141.
Yang S, Jin H, Zhu Y, Wan Y, Opoku EN, Zhu L, et al. Diverse
Functions and Mechanisms of Pericytes in Ischemic Stroke. Curr
Neuropharmacol. 2017;15:892-905.
142.
Villasenor R, Kuennecke B, Ozmen L, Ammann M, Kugler C,
Gruninger F, et al. Region-specific permeability of the blood-brain barrier
upon pericyte loss. J Cereb Blood Flow Metab. 2017;37:3683-3694.
143.
Bandopadhyay R, Orte C, Lawrenson JG, Reid AR, de Silva S and
Allt G. Contractile proteins in pericytes at the blood brain and blood retinal
barriers. Journal of Neurocytology. 2001;30:35-44.
144.
Boado RJ and Pardridge WM. Differential expression of alpha actin
mRNA and immunoreactive protein in brain microvascular pericytes and
smooth muscle cells. Journal of Neuroscience Research. 1994;39:430-435.
145.
Dalkara T and Arsava EM. Can restoring incomplete microcirculatory
reperfusion improve stroke outcome after thrombolysis? J Cereb Blood
Flow Metab. 2012;32:2091-2099.
146.
Hall CN, Reynell C, Gesslein B, Hamilton NB, Mishra A, Sutherland
BA, et al. Capillary pericytes regulate cerebral blood flow in health and
disease. Nature. 2014;508:55-6
147.
Rezkalla SH and Kloner RA. No-reflow phenomenon. Circulation.
2002;105:656-662.
148.
Lu JX, Lu ZQ, Zhang SL, Zhi J, Chen ZP and Wang WX.
Polymorphism in Integrin ITGA2 is Associated with Ischemic Stroke and
Altered Serum Cholesterol in Chinese Individuals. Balkan Med J.
2014;31:55-59.
149.
Greenberg DA. Cerebral angiogenesis: a realistic therapy for
ischemic disease? Methods Mol Biol. 2014;1135:21-24.
150.
Stapor PC, Sweat RS, Dashti DC, Betancourt AM and Murfee WL.
Pericyte dynamics during angiogenesis: new insights from new identities. J
Vasc Res. 2014;51:163-174.
142

151.
Krupiński J, Kałuza J, Kumar P, Kumar S and Wang JM. Some
remarks on the growth-rate and angiogenesis of microvessels in ischemic
stroke. Morphometric and immunocytochemical studies. Patologia Polska.
1993;44:203-209.
152.
Navaratna D, Guo S, Arai K and Lo EH. Mechanisms and targets for
angiogenic therapy after stroke. Cell Adhesion and Migration. 2009;3:216223.
153.
Sun Y, Zeng Y, Zhu Y, Feng F, Xu W, Wu C, et al. Application of
(68)Ga-PRGD2 PET/CT for alphavbeta3-integrin imaging of myocardial
infarction and stroke. Theranostics. 2014;4:778-786.
154.
Pan R, Yu K, Weatherwax T, Zheng H, Liu W and Liu KJ. Blood
Occludin Level as a Potential Biomarker for Early Blood Brain Barrier
Damage Following Ischemic Stroke. Sci Rep. 2017;7:40331.
155.
Pickering J, Chow L, Li S, Rogers K, Rocnik E, Zhong R, et al. a5b1
integrin expression and luminal edge fibronectin matrix assembly by smooth
muscle cells after arterial injury. American Journal of Pathology.
2000;156:453-465.
156.
Donate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, et al.
Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCNNH2): Observation of a U-Shaped Dose-Response Curve in Several
Preclinical Models of Angiogenesis and Tumor Growth. Clinical Cancer
Research. 2008;14:2137-2144.
157.
Magnuson MA, Kasman IA, Norberg S, Baluk P and Murray R. Rapid
Access of Antibodies to a5b1 Integrin Overexpressed on the Luminal
Surface of Tumor Blood Vessels. Cancer Research. 2005;65:2712-2721.
158.
Edwards D and Bix G. Roles of integrins and extracellular matrix
proteins after ischemic stroke. American Journal of Cell Physiology. 2018.
Online ahead of print.
159.
Cianfrocca ME, Kimmel KA, Gallo J, Cardoso T, Brown MM, Hudes
G, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCNNH(2)), a beta integrin antagonist, in patients with solid tumours. Br J
Cancer. 2006;94:1621-1626.
160.
Matter M, Zhang Z, Nordstedt C and Ruoslahti E. The a5b1 integrin
mediates eliminiation of amyloid-b peptide and protects against apoptosis.
J Cell Biol. 1998;141:1019-1030.

143

161.
Plow EF, Haas TA, Zhang L, Loftus J and Smith JW. Ligand binding
to integrins. J Biol Chem. 2000;275:21785-21788.
162.
Barone F and Feuerstein G. Inflammatory Meidators and Stroke:
new opportunites for novel therapeutics. Journal of Cerebral Blood Flow and
Metabolism. 1999;19:819-834.
163.
Harris ES, McIntyre TM, Prescott SM and Zimmerman GA. The
leukocyte integrins. J Biol Chem. 2000;275:23409-23412.
164.
Stefanidakis M and Koivunen E. Cell-surface association between
matrix metalloproteinases and integrins: role of the complexes in leukocyte
migration and cancer progression. Blood. 2006;108:1441-1450.
165.
del Zoppo G. Microvascular changes during cerebral ischemia and
reperfusion. Cerebrovasc Brain Metab Rev. 1994;6:47-96.
166.
Dereski M, Chopp M, Knight R, Rodolosi L and Garcia J. The
heterogeneous temporal evolution of focal ischmiec neuronal damage in the
rat. Acta Neuropathol. 1993;85:327-333.
167.
Yonekawa K and Harlan JM. Targeting leukocyte integrins in human
diseases. J Leukoc Biol. 2005;77:129-140.
168.
Bargatze R, Kurk S, Butcher E and Jutila M. Neutrophils roll on
adherant neutrophils bound to cytokine-induced endothelial cells via Lselectin on the rolling cells. Journal of Experimental Methodology.
1994;180:1785-1792.
169.
Zhang R, Chopp M, Zhang Z, Jiang N and Powers C. The expression
of P- and E-selectins in three models of middle cerebral artery occlusion.
Brain Research. 1998;785:207-214.
170.
Lauffenburger D and Horowitz AF. Cell migration: A physically
integrated molecular process. Cell. 1996;84:359-369.
171.
Ridley A, Schwartz M, Burridge K, Firtel R, Ginsberg M, Borisy G, et
al. Cell migration: integrating signals from front to back. Science.
2003;302:1704-1709.
172.
del Pozo M, Sanchez-Mateos P, Nieto M and Sanchez-Madrid F.
Chemokines regulate cellular polarization and adhesion receptor
redistribution during lymphocyte interaction with endothelium and
extracellular matrix. Involvement of cAMP signaling pathway. Journal of Cell
Biology. 1995;131:495-508.
173.
Lorant D, McEver R, McIntyre TM, Moore K, Prescott SM and
Zimmerman GA. Activation of polymorphonuclear leukocytes reduces their
144

adhesion to P-selectin and causes redistribution of ligands for P-selectin on
their surfaces. Journal for Clinical Investigations. 1995;96:171-182.
174.
Becker K. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and
Enlimomab (R6.5) in acute stroke. Current Medicical Research and
Opinion. 2002;18:18-22.
175.
Kindzelskii A, Laska Z, Tod R and Petty H. Urokinase-type
plasminogen activator receptor reversibly dissociates from complement
receptor type 3(alpha M beta 2’ CD11b/CD18) during neutrophil
polarization. J Immunol. 1996;156:297-309.
176.
Huang J, Upadhyay UA and Tamargo RJ. Inflammation in stroke and
focal cerebral ischemia. Surgical Neurology. 2006;66:232-245.
177.
Schofield ZV, Woodruff TM, Halai R, Wu MC and Cooper MA.
Neutrophils--a key component of ischemia-reperfusion injury. Shock.
2013;40:463-470.
178.
Weston RM, Jones NM, Jarrott B and Callaway JK. Inflammatory cell
infiltration after endothelin-1-induced cerebral ischemia: histochemical and
myeloperoxidase correlation with temporal changes in brain injury. J Cereb
Blood Flow Metab. 2007;27:100-114.
179.
Aspey B, Jessimer C, Pereira S and Harrison M. Do leukocytes have
a role in the cerebral no-reflow phenomenon? Journal of Neurology,
Neurosurgery, and Psychiatry. 1989;52:526-528.
180.
Enzmann G, Mysiorek C, Gorina R, Cheng YJ, Ghavampour S,
Hannocks MJ, et al. The neurovascular unit as a selective barrier to
polymorphonuclear granulocyte (PMN) infiltration into the brain after
ischemic injury. Acta Neuropathol. 2013;125:395-412.
181.
Chou W, Choi D, Zhang H, Mu D, McMahon T, Kharazia V, et al.
Neutrophil protein kinase Cδ as a mediator of stroke-reperfusion injury.
Jounral of Clinical Investigation. 2004;114:49-56.
182.
Ishikawa M, Vowinkel T, Stokes KY, Arumugam TV, Yilmaz G,
Nanda A, et al. CD40/CD40 ligand signaling in mouse cerebral
microvasculature
after
focal
ischemia/reperfusion.
Circulation.
2005;111:1690-1696.
183.
Schroeter M, Jander S, Witte O and Stoll G. Local immune
responses in the rat cerebral cortex after middle cerebral artery occlusion.
Journal of Neuroimmunology. 1994;55:195-203.

145

184.
Stevens S, Bao J, Hollis J, Lessov N, Clark W and Stenzel-Poore M.
The use of flow cytometry to evaluate temporal changes in inflammatory
cells follwoing focal cerebral ischemia in mice. Brain Research.
2002;932:110-119.
185.
Brait VH, Rivera J, Broughton BR, Lee S, Drummond GR and Sobey
CG. Chemokine-related gene expression in the brain following ischemic
stroke: no role for CXCR2 in outcome. Brain Res. 2011;1372:169-179.
186.
Yilmaz G, Arumugam TV, Stokes KY and Granger DN. Role of T
lymphocytes and interferon-gamma in ischemic stroke. Circulation.
2006;113:2105-2112.
187.
Shichita T, Sugiyama Y, Ooboshi H, Sugimori H, Nakagawa R,
Takada I, et al. Pivotal role of cerebral interleukin-17-producing
gammadeltaT cells in the delayed phase of ischemic brain injury. Nat Med.
2009;15:946-950.
188.
Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz
T, et al. Early detrimental T-cell effects in experimental cerebral ischemia
are neither related to adaptive immunity nor thrombus formation. Blood.
2010;115:3835-3842.
189.
Tarkowski E, Naver H, Wallin B, Blomstrand C and Tarkowski A.
Lateralization of T-lymphocyte responses in pathients with stroke. Effect of
sympathetic dysfunction? Stroke. 1995;26:57-62.
190.
Nadareishvili Z, Li H, Wright V, Maric D, Warach S, Hallenbeck J, et
al. Elevated pro-inflammatory CD4+CD28+ lymphocytes and stroke
recurrence and death. Neurology. 2004;63:1446-1451.
191.
Engelhardt B and Sorokin L. The blood-brain and the bloodcerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol.
2009;31:497-511.
192.
Askari JA, Buckley PA, Mould AP and Humphries MJ. Linking
integrin conformation to function. J Cell Sci. 2009;122:165-170.
193.
Ley K, Laudanna C, Cybulsky MI and Nourshargh S. Getting to the
site of inflammation: the leukocyte adhesion cascade updated. Nat Rev
Immunol. 2007;7:678-689.
194.
Chavakis T. Leucocyte recruitment in inflammation and novel
endogenous negative regulators thereof. European Journal of Clinical
Investigation. 2012;42:686-691.

146

195.
Hyun Y, Lefort C and Kim M. Leukocyte integrins and their ligand
interactions. Immunology Research. 2009;45:95-208.
196.
Mitroulis I, Alexaki VI, Kourtzelis I, Ziogas A, Hajishengallis G and
Chavakis T. Leukocyte integrins: role in leukocyte recruitment and as
therapeutic targets in inflammatory disease. Pharmacol Ther.
2015;147:123-135.
197.
Herter J and Zarbock A. Integrin Regulation during Leukocyte
Recruitment. J Immunol. 2013;190:4451-4457.
198.
Schenkel AR, Mamdouh Z and Muller WA. Locomotion of monocytes
on endothelium is a critical step during extravasation. Nat Immunol.
2004;5:393-400.
199.
Schittenhelm L, Hilkens CM and Morrison VL. beta2 Integrins As
Regulators of Dendritic Cell, Monocyte, and Macrophage Function. Front
Immunol. 2017;8:1866.
200.
Lindbom L and Werr J. Integrin-dependent neutrophil migration in
extravascular tissue. Semin Immunol. 2002;14:115-121.
201.
Pierini LM, Lawson MA, Eddy RJ, Hendey B and Maxfield FR.
Oriented endocytic recycling of a5b1 in motile neutrophils. Blood.
2000;95:2471-2480.
202.
Gerhard A, Neumaier B, Elitok E, Glatting G, Tomczak R, Ludolph A,
et al. In vivo imaging of activated microglia using [11C]PK11195 and
positron emission tomography in patients after ischemic stroke.
Neuroreport. 2000;11:2957-2960.
203.
Zhao H, Dong X, Wang X, Li X, Zhuang F, Stoltz JF, et al. Studies
on single-cell adhesion probability between lymphocytes and endothelial
cells with micropipette technique. Microvasc Res. 2002;63:218-226.
204.
Frijns C and Kappelle L. Inflammatory cell adhesion molecules in
ischemic cerebrovasclar disease. Stroke. 2002;33:2115-2122.
205.
Hammond MD, Ambler WG, Ai Y and Sansing LH. alpha4 integrin is
a regulator of leukocyte recruitment after experimental intracerebral
hemorrhage. Stroke. 2014;45:2485-2487.
206.
Walling BL and Kim M. LFA-1 in T Cell Migration and Differentiation.
Front Immunol. 2018;9:952.
207.
Kuwano Y, Spelten O, Zhang H, Ley K and Zarbock A. Rolling on Eor P-selectin induces the extended but not high-affinity conformation of LFA1 in neutrophils. Blood. 2010;116:617-624.
147

208.
Steffen B, Butcher E and Engelhardt B. Evidence for involvement of
ICAM-1 and VCAM-1 in lymphocyte interaction with endothelium in
experimental autoimmune encephalomyelitis in the central nervous system
in the SJL/J mouse. American Journal of Pathology. 1994;145:189-201.
209.
Greenwood J, Wang Y and Calder V. Lymphocyte adhesion and
transendothelial migration in the central nervous system: the role of LFA-1,
ICAM-1, VLA-4 and VCAM-1. off. Immunology. 1995;86:408-415.
210.
Ghandour H, Cultere X, Alvarez A, Luscinskas F and Mayadas T.
Essential role for Rap1 GTPase and its guanine exchange factor CalDAGGEFI in LFA-1 but not VLA-4 integrin mediated human T-cell adhesion.
Blood. 2007;110:3682-3690.
211.
Marlin S and Springer T. Purified intercellular adhesion molecule-1
(ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1).
Cell. 1987;51:813-819.
212.
de Fougerolles A, Qin X and Springer T. Characterization of the
function of intercellular adhesion molecule (ICAM)-3 and comparison with
ICAM-1 and ICAM-2 in immune responses. Journal of Experimental
Medicine. 1994;179:619-629.
213.
de Fougerolles A, Stacker S, Schwarting R and Springer T.
Characterization of ICAM-2 and evidence for a third counter-receptor for
LFA-1. Journal of Experimental Medicine. 1991;174:253-267.
214.
Tian L, Kilgannon P, Yoshihara Y, Mori K, Gallatin W, Carpen O, et
al. Binding of T lymphocytes to hippocampal neurons through ICAM-5
(telencephalin) and characterization of its interaction with the leukocyte
integrin CD11a/CD18. European Journal of Immunology. 2000;30:810-818.
215.
Katakai T, Habiro K and Kinashi T. Dendritic cells regulate highspeed interstitial T cell migration in the lymph node via LFA-1/ICAM-1. J
Immunol. 2013;191:1188-1199.
216.
Dominguez GA, Anderson NR and Hammer DA. The direction of
migration of T-lymphocytes under flow depends upon which adhesion
receptors are engaged. Integr Biol (Camb). 2015;7:345-355.
217.
Price CJ, Menon DK, Peters AM, Ballinger JR, Barber RW, Balan
KK, et al. Cerebral neutrophil recruitment, histology, and outcome in acute
ischemic stroke: an imaging-based study. Stroke. 2004;35:1659-1664.

148

218.
Buck BH, Liebeskind DS, Saver JL, Bang OY, Yun SW, Starkman S,
et al. Early neutrophilia is associated with volume of ischemic tissue in acute
stroke. Stroke. 2008;39:355-360.
219.
Arumugam TV, Salter JW, Chidlow JH, Ballantyne CM, Kevil CG and
Granger DN. Contributions of LFA-1 and Mac-1 to brain injury and
microvascular dysfunction induced by transient middle cerebral artery
occlusion. Am J Physiol Heart Circ Physiol. 2004;287:H2555-2560.
220.
Park EJ, Peixoto A, Imai Y, Goodarzi A, Cheng G, Carman CV, et al.
Distinct roles for LFA-1 affinity regulation during T-cell, diapedesis, and
interstitial migration in lymph nodes. Immunology. 2010;115:1572-1581.
221.
Shaw SK, Ma S, Kim MB, Rao RM, Hartman CU, Froio RM, et al.
Coordinated redistribution of leukocyte LFA-1 and endothelial cell ICAM-1
accompany neutrophil transmigration. J Exp Med. 2004;200:1571-1580.
222.
Danton G and Dietrich W. Inflammatory mechanisms after ischemia
and stroke. Journal of Neuropathology and Experimental Neurology.
2003;62:127-136.
223.
Hess D, Zhao W, Carroll J, McEachin M and Buchanan K. Increased
expression of ICAM-1 during reoxygenation in brain endothelial cells.
Stroke. 1994;25:1463-1468.
224.
Hess DC, Bhutwala T, Sheppard J, Zhao W and Smith J. ICAM-1
expression on human brain microvascular endothelial cells. Neuroscience
Letters. 1994;168:201-204.
225.
Zhang Z, Chopp M, Tang W, Jiang N and Zhang R. Post-ischemic
treatment (2-4 h) with anti-CDllb and anti-CD18 monoclonal antibodies are
neuroprotective after transient (2 h) focal cerebral ischemia in the rat. Brain
Research. 1995;698:79-85.
226.
Wang Q, Tang X and Yenari M. The inflammatory response in
stroke. Journal of Neuroimmunology. 2007;184:53-68.
227.
Shyu K, Chang H and Lin C. Serum levels of intercellular adhesion
molecule-1 and E-selectin in patients with acute ischaemic stroke. Journal
of Neuroscience. 1997;244:90-93.
228.
Kaplanski G, Farnarier C, Benoliel A, Foa C, Kaplanski S and
Bongrand P. A novel role for E- and P-selectins:shape control of endothelial
cell monolayers. J Cell Sci. 1994;107:2449-2457.
229.
Vemuganti R, Dempsey RJ and Bowen KK. Inhibition of intercellular
adhesion molecule-1 protein expression by antisense oligonucleotides is
149

neuroprotective after transient middle cerebral artery occlusion in rat.
Stroke. 2004;35:179-184.
230.
Connolly E, Winfree C, Springer TA, Naka Y, Liao H, Yan S, et al.
Cerebral Protection in Homozygous Null ICAM-1 Mice after Middle Cerebral
Artery Occlusion. Journal of Clinical Investigation. 1996;97:209-216.
231.
Kitagawa K, Matsumoto M, Mabuchi T, Yagita Y, O’htsuki T, Hori M,
et al. Deficiency of Intercellular Adhesion Molecule 1 Attenuates
Microcirculatory Disturbance and Infarction Size in Focal Cerebral
Ischemia. Journal of Cerebral Blood Flow and Metabolism. 1998;18:13361345.
232.
Furuya K, Takeda H, Azhar S, McCarron R, Chen Y, Ruetzler C, et
al. Examination of several potential mechanisms for the negative outcome
in a clinical stroke trial of enlimomab, a murine anti-human intercellular
adhesion molecule-1 antibody: a bedside-to-bench study. Stroke.
2001;32:2665-2674.
233.
Springer TA, Galfre G, Secher D and Milstein C. Mac-1: a
macrophage differentiation antigen identified by monoclonal antibody.
European Journal of Immunology. 1979;9:301-306.
234.
von Andrian U, Chambers J, McEvoy L, Bargatze R, Arfors K and
Butcher E. Two-step model of leukocyte-endothelial cell interaction in
inflammation: Distinct roles for LECAM-1 and the leukocyte beta2 integrins
in vivo. Proceedings of the National Academy of Sciences of the United
States of America. 1991;88:7538-7542.
235.
Cai T and Wright S. Human Leukocyte Elastase Is an Endogenous
Ligand for the Integrin CR3 (CDllb/CD18, Mac-l, alphaM beta2) and
Modulates Polymorphonuclear Leukocyte Adhesion. Journal of
Experimental Medicine. 1996;184:1213-1223.
236.
Micklem K and Sim R. Isolation of complement-fragment-iC3bbinding proteins by affintiy chromatography. Biochemistry. 1985;231:233236.
237.
Chavakis T, May A, Preissner K and Kanse S. Molecular
mechanisms of zinc-dependent leukocyte adhesion involving the urokinase
receptor and B2-integrins. Blood. 1999;93:2976-2983.
238.
Stanimirovic D, Wong J, Shapiro A and Durkin J. Increase in surface
expression of ICAM-1, VCAM-1 and E-selectin in human

150

cerebromicrovascular endothelial cells subjected to ischemia-like insults.
Acta Neurochir Suppl. 1997;70:12-16.
239.
Lub M, van Koyk Y and Figdor C. Competition between lymphocyte
function-associated antigen 1 (CD11a/CD18) and Mac-1 (CD11b/CD18) for
binding to intercellular adhesion molecule-1 (CD54). Journal of Leukocyte
Biology. 1996;59:648-655.
240.
Campanella M, Sciorati C, Tarozzo G and Beltramo M. Flow
cytometric analysis of inflammatory cells in ischemic rat brain. Stroke.
2002;33:586-592.
241.
Chen H, Chopp M, Zhang R, Bodzin G, Chen Q, Rusche J, et al.
Anti-CD11b monoclonal antibody reduces ischemic cell damage after
transient focal cerebral ischemia in rat. Annals of Neurology. 1994;35:458463.
242.
Bowes M, Rothlein R, Fagan S and Zivin J. Monoclonal antibodies
preventing leukocyte activation reduce experimental neurologic injury and
enhance efficacy of thrombolytic therapy. Neurology. 1995;45:815-819.
243.
Jiang N, Chopp M and Chahwala S. Neutrophil inhibitory factor
treatment of focal cerebral ishcemia in the rat. Brain Research.
1998;788:25-34.
244.
Zhang L, Zhang ZG, Zhang RL, Lu M, Krams M and Chopp M. Effects
of a selective CD11b/CD18 antagonist and recombinant human tissue
plasminogen activator treatment alone and in combination in a rat embolic
model of stroke. Stroke. 2003;34:1790-1795.
245.
Lebwhohl M, Tyring S, Hamilton T, Toth D, Glazer S, Tawflk N, et al.
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. New
England Journal of Medicine. 2003;349:2004-2013.
246.
Yenari MA, Kunis D, Sun G, Onley D, Watson L, Turner S, et al.
Hu23F2G, an antibody recognizing the leukocyte CD11/CD18 integrin,
reduces injury in a rabbit model of transient focal cerebral ischemia.
Experimental Neurology. 1998;153:223-233.
247.
Becker K. Anti-leukocyte antibodies: LeukArrest (Hu23F2G) and
Enlimomab (R6.5) in acute stroke. Current Medicical Research and
Opinion. 2002;18:18-22.
248.
Krams M, Lees KR, Hacke W, Grieve AP, Orgogozo JM, Ford GA,
et al. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an

151

adaptive dose-response study of UK-279,276 in acute ischemic stroke.
Stroke. 2003;34:2543-2548.
249.
Caimi G, Canino B, Ferrara F, Montana M, Musso M, Porretto F, et
al. Granulocyte integrins before and after activation in acute ischaemic
stroke. Journal of the Neurological Sciences. 2001;186:23-26.
250.
Campanero M, Sanchez-Mateos P, del Pozo M and Sanchez-Madrid
F. ICAM-3 regulates lymphocyte morphology and integrin-mediated T cell
interaction with endothelial cell and extracellular matrix ligands. Journal of
Cell Biology. 1994;127:867-878.
251.
Lobb RR and Hemler ME. The pathophysiologic role of alpha 4
integrins in vivo. J Clin Invest. 1994;94:1722-1728.
252.
Vajkoczy P, Laschinger M and Engelhardt B. α4-integrin-VCAM-1
binding mediates G protein–independent capture of encephalitogenic T cell
blasts to CNS white matter microvessels. Journal of Clinical Investigation.
2001;108:557.
253.
Luo BH, Carman CV and Springer TA. Structural basis of integrin
regulation and signaling. Annu Rev Immunol. 2007;25:619-647.
254.
Liesz A, Zhou W, Mracsko E, Karcher S, Bauer H, Schwarting S, et
al. Inhibition of lymphocyte trafficking shields the brain against deleterious
neuroinflammation after stroke. Brain. 2011;134:704-720.
255.
Langhauser F, Kraft P, Gob E, Leinweber J, Schuhmann MK, Lorenz
K, et al. Blocking of alpha4 integrin does not protect from acute ischemic
stroke in mice. Stroke. 2014;45:1799-1806.
256.
Llovera G, Hofmann K, Roth S, Salas-Perdomo A, Ferrer-Ferrer M,
Perego C, et al. Results of a preclinical randomized controlled multicenter
trial (pRCT): Anti-CD49d treatment for acute brain ischemia. Science
Translational Medicine. 2015;7:299ra121.
257.
Relton J, Sloan K, Frew E, Whalley E, Adams S and Lobb R.
Inhibition of alpha4 integrins protects against transient focal cerebral
ischemia in normotensive and hypertensive rats. Stroke. 2000;32:199-205.
258.
Labus J, Woltje K, Stolte KN, Hackel S, Kim KS, Hildmann A, et al.
IL-1beta promotes transendothelial migration of PBMCs by upregulation of
the FN/alpha5beta1 signalling pathway in immortalised human brain
microvascular endothelial cells. Exp Cell Res. 2018;373:99-111.
259.
Gronholm M, Jahan F, Bryushkova EA, Madhavan S, Aglialoro F,
Soto Hinojosa L, et al. LFA-1 integrin antibodies inhibit leukocyte
152

alpha4beta1-mediated adhesion by intracellular signaling. Blood.
2016;128:1270-1281.
260.
Bohnsack J. CD18-independent neutrophil adherence to laminin is
mediated by the integrin VLA-6 Blood. 1992;79:1545-1552.
261.
Loike J, Cao L, Budhu S, Maracantonio E, Khoury J, Hoffman S, et
al. Differential Regulation of b1 Integrins by Chemoattractants Regulates
Neutrophil Migration through Fibrin. Journal of Cell Biology. 1999;144:10471056.
262.
Bretscher M. Moving membrane up to the front of migrating cells.
Cell. 1996;85:465-467.
263.
Edwards D, Salmeron K, Lukins D, Trout A, Fraser JF and Bix GJ.
Integrin a5b1 inhibition by ATN-161 reduces blood-brain barrier
permeability, neuroinflammation, and is neuroprotective. Abstract,
International Stroke Conference 2019.
264.
Polman C, O’’Conner P, Havrdova E, Hutchinson M, Kappos L, Miller
D, et al. A randomized, placebo-controlled trial of natalizumab for relapsing
multiple sclerosis. New England Journal of Medicine. 2006;354:899-910.
265.
Sandborn W, Colombel J, Enns R, Feagen B, Hanauer S, Lawrence
I, et al. Natalizumab induction and maintenance therapy for crohn's disease.
New England Journal of Medicine. 2015;372:2074.
266.
Elkins J, Vetkamp R, Montaner J, Johnston S, Singhal A, Becker K,
et al. Safety and efficacy of natalizumab in patients with acute ischaemic
stroke (ACTION): a randomized, placebo-controlled, double-blind phase 2
trial. Lancet Neurology. 2017;16:217-226.
267.
Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick
PB, et al. Stroke Treatment Academic Industry Roundtable (STAIR)
recommendations for maximizing the use of intravenous thrombolytics and
expanding treatment options with intra-arterial and neuroprotective
therapies. Stroke. 2011;42:2645-2650.
268.
Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, OrtegaGutierrez S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection
by Perfusion Imaging. N Engl J Med. 2018;378:708-718.
269.
Mendez AA, Samaniego EA, Sheth SA, Dandapat S, Hasan DM,
Limaye KS, et al. Update in the Early Management and Reperfusion
Strategies of Patients with Acute Ischemic Stroke. Crit Care Res Pract.
2018;2018:9168731.
153

270.
Baeten KM and Akassoglou K. Extracellular Matrix and Matrix
Receptors in Blood-Brain Barrier Formation and Stroke. Developmental
Neurobiology. 2011;71:1018-1039.
271.
Huveneers S, Truong H and Danen HJ. Integrins: signaling, disease,
and therapy. Int J Radiat Biol. 2007;83:743-751.
272.
Park EJ, Yuki Y, Kiyono H and Shimaoka M. Structural basis of
blocking integrin activation and deactivation for anti-inflammation. J Biomed
Sci. 2015;22:51.
273.
Milner R, Hung S, Erokwu B, Dore-Duffy P, LaManna JC and del
Zoppo GJ. Increased expression of fibronectin and the alpha 5 beta 1
integrin in angiogenic cerebral blood vessels of mice subject to hypobaric
hypoxia. Mol Cell Neurosci. 2008;38:43-52.
274.
Grupke S, Hall J, Dobbs M, Bix GJ and Fraser JF. Understanding
history, and not repeating it. Neuroprotection for acute ischemic stroke: from
review to preview. Clin Neurol Neurosurg. 2015;129:1-9.
275.
Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al.
User-guided 3D active contour segmentation of anatomical structures:
significantly improved efficiency and reliability. Neuroimage. 2006;31:11161128.
276.
Luheshi NM, Kovacs KJ, Lopez-Castejon G, Brough D and Denes A.
Interleukin-1alpha expression precedes IL-1beta after ischemic brain injury
and is localised to areas of focal neuronal loss and penumbral tissues. J
Neuroinflammation. 2011;8:186.
277.
Selvaraj UM, Ortega SB, Hu R, Gilchrist R, Kong X, Partin A, et al.
Preconditioning-induced CXCL12 upregulation minimizes leukocyte
infiltration after stroke in ischemia-tolerant mice. J Cereb Blood Flow Metab.
2017;37:801-813.
278.
Khalili P, Arakelian A, Chen G, Plunkett ML, Beck I, Parry GC, et al.
A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer
growth and metastasis in vivo. Mol Cancer Ther. 2006;5:2271-2280.
279.
Guell K and Bix GJ. Brain endothelial cell specific integrins and
ischemic stroke. Expert Review of Neurotherapeutics. 2014;14:1287-1292.
280.
Yu SW, Friedman B, Cheng Q and Lyden PD. Stroke-evoked
angiogenesis results in a transient population of microvessels. J Cereb
Blood Flow Metab. 2007;27:755-763.

154

281.
Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, et al. Sizeselective loosening of the blood-brain barrier in claudin-5-deficient mice. J
Cell Biol. 2003;161:653-660.
282.
Lorenz HM, Lagoo AS and KHardy KJ. The Cell and Molecular Basis
of Leukocyte Common Antigen (CD45)- Triggered, Lymphocyte FunctionAssociated Antigen-l -/Intercellular Adhesion Molecule-l-Dependent,
Leukocyte Adhesion. Blood. 1994;83:1862-1870.
283.
Luscinaskas FW, Kansas GS, Ding H, Pizcueta P, Schleiffenbaum
BE, Tedder TF, et al. Monocyte Rolling, Arrest and Spreading on IL-4activated Vascular Endothelium under Flow Is Mediated via Sequential
Action of L-Selectin, b1-Integrins, and b2-Integrins. The Journal of Cell
Biology. 1994;125:1417-1427.
284.
Park EJ, Yuki Y, Kiyono H and Shimaoka M. Structural basis of
blocking integrin activation and deactivation for anti-inflammation. J Biomed
Sci. 2015;22:51.
285.
Laukaitis CM, Webb DJ, Donais K and Horowitz AF. Differential
Dynamics of a5 Integrin, Paxillin, and a-Actinin during Formation and
Disassembly of Adhesions in Migrating Cells. The Journal of Cell Biology.
2001;153:1427-1440.
286.
Stanley P, Tooze S and Hogg N. A role for Rap2 in recycling the
extended conformation of LFA-1 during T cell migration. Biol Open.
2012;1:1161-1168.
287.
Ohno T, Yamamoto G, Hayashi JI, Nishida E, Goto H, Sasaki Y, et
al. Angiopoietin-like protein 2 regulates Porphyromonas gingivalis
lipopolysaccharide-induced inflammatory response in human gingival
epithelial cells. PLoS One. 2017;12:e0184825.
288.
Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo
EH and Montaner J. MMP-9-positive neutrophil infiltration is associated to
blood-brain barrier breakdown and basal lamina type IV collagen
degradation during hemorrhagic transformation after human ischemic
stroke. Stroke. 2008;39:1121-1126.
289.
Liu J, Wang Y, Akamatsu Y, Lee CC, Stetler RA, Lawton MT, et al.
Vascular remodeling after ischemic stroke: mechanisms and therapeutic
potentials. Prog Neurobiol. 2014;115:138-156.

155

290.
Wu CC, Wang LC, Su YT, Wei WY and Tsai KJ. Synthetic
alpha5beta1 integrin ligand PHSRN is proangiogenic and neuroprotective
in cerebral ischemic stroke. Biomaterials. 2018;185:142-154.
291.
Feng Y and Mrksich M. The Synergy Peptide PHSRN and the
Adhesion Peptide RGD Mediate Cell Adhesion through a Common
Mechanism. Biochemistry. 2004;43:15811-15821.
292.
Lathia JD, Chigurupati S, Thundyil J, Selvaraj PK, Mughal MR,
Woodruff TM, et al. Pivotal role for beta-1 integrin in neurovascular
remodelling after ischemic stroke. Exp Neurol. 2010;221:107-114.
293.
Paul Nikki R, Jacquemet G and Caswell Patrick T. Endocytic
Trafficking of Integrins in Cell Migration. Current Biology. 2015;25:R1092R1105.
294.
Turolla A, Venneri A, Farina D, Cagnin A and Cheung VCK.
Rehabilitation Induced Neural Plasticity after Acquired Brain Injury. Neural
Plast. 2018;2018:6565418.
295.
Font M, Arboix A and Krupiński J. Angiogenesis, Neurogenesis, and
Neuroplasticity in Ischemic Stroke. Curr Cardiol Rev. 2010;6:238-244.
296.
Livant D, Brabex R, Kurachi K, Allen D, Wu Y, Haaseth R, et al. The
PHSRN sequence induces extracellular matrix invasion and accelerates
wound healing in ovese diabetic mice. J Clin Invest. 2000;105:1537-1545.
297.
Turner P, Brabb T, Pekow C and Vasbinder M. Administration of
Substrances to Laboratory Animals: Routes of Administration and Factors
to Consider. J Ameri Ass Lab Ani Sci. 2011;50:600-613.
298.
Jickling GC, Liu D, Ander BP, Stamova B, Zhan X and Sharp FR.
Targeting Neutrophils in Ischemic Stroke: Translational Insights from
Experimental Studies. Journal of Cerebral Blood Flow & Metabolism.
2015;35:888-901.
299.
Herz J, Sabellek P, Lane TE, Gunzer M, Hermann DM and Doeppner
TR. Role of Neutrophils in Exacerbation of Brain Injury After Focal Cerebral
Ischemia in Hyperlipidemic Mice. Stroke. 2015;46:2916-2925.
300.
Cramer SC. Treatments to Promote Neural Repair after Stroke. J
Stroke. 2018;20:57-70.
301.
Roberts JM, Maniskas ME and Bix GJ. Bilateral carotid artery
stenosis causes unexpected early changes in brain extracellular matrix and
blood-brain barrier integrity in mice. PLoS One. 2018;13:e0195765.

156

Vita
Danielle Nichele Edwards
Educational Institutions
University of Kentucky
Doctoral Candidate – Neuroscience
University of Kentucky
Bachelor of Science – Chemistry
Year of Graduation - 2014
Research and Professional Experience
Graduate Student, University of Kentucky
Co-Mentor: Gregory J Bix, MD PhD
Co-Mentor: Justin F Fraser, MD
Undergraduate Research Assistant, University of Kentucky
Mentor: Beth Guiton, PhD
Scholastic and Professional Honors
Center for Clinical Translational Science TL1
Neuroscience Travel Award
University of Kentucky College of Medicine Travel Award
University of Kentucky Graduate Student Congress Travel Award

2016-2018
2017
2017
2016

Teaching and Professional Development
Graduate Teaching Certificate in Gross Anatomy
Graduate Teaching Certificate in Neuroscience
CELT Seminar: Meditation and Reflection in the Classroom
CELT Seminar: But I read it on the internet?!?!
CELT Seminar: Teacher Course Evaluations
CELT Seminar: Building a Teaching Portfolio
ANA 209 Teaching Assistant

2018
2018
2018
2018
2018
2017
2016-2017

Peer Reviewed Publications
Edwards DN and Bix GJ. The inflammatory response after ischemic stroke:
Targeting B2 and B1 Integrins. Frontiers of Neuroscience. In Preparation.
157

Trout A, Khale MP, Marcelo A, Roberts J, de Hoog L, Boychuch, JA, Grupke SL,
Beretta A, Gowing EK, Boychuch CR, Gorman A, Edwards DN, Ishibashi-Ueda H,
Ihara M, Smith BN, Clarkson AN, and Bix GJ. Perlecan Domain-V Treatment
Enhances Neurogenic Brain Repair and Functional Recovery after Experimental
Ischemic Stroke. JCI. 2018; In revision.
Salmeron KE, Maniskas ME, Edwards DN, Wong R, Trout AL, Hamilton S, JF,
Pinteaux E, and Bix GJ (2018) Interleukin 1 is profoundly neuroprotective and
neurorestorative following experimental ischemic stroke. In Revision.
Edwards DN, Salmeron S, Lukins DE, Fraser JF, and Bix GJ. ATN-161 is
neuroprotective after experimental ischemic stroke through inhibition of integrin
α5β1 by the small peptide, ATN-161. Stroke. In Revision
Edwards DN and Bix GJ. Roles of integrins and extracellular matrix in stroke.
American Journal of Cell Physiology. Nov 2018. ePub.
Fraser JF, Collier LA, Gorman AA, Martha SR, Salmeron KE, Trout AL, Edwards
DN, Davis SM, Lukins DE, Alhajeri A, Grupke S, Roberts JM, Bix GJ, and
Pennypacker K. The Blood And Clot Thrombectomy Registry And Collaboration
(BACTRAC) protocol: novel method for evaluating human stroke. K NeuroIntervent
Surg. 2018; 0:1-6.
Salmeron KE, Edwards DN, Fraser JF, and Bix GJ, (2017) Edema and BBB
Breakdown in Stroke. In Jérôme Badaut and Nikolaus Plesnila, editors: Badaut -ˇ
BRAIN EDEMA, Oxford: Academic Press. 2017;217- 234.
Hudak BM, Chang Y-J, Yu L, Li G, Edwards DN, and Guiton BS. (2014) Real-time
observation of the solid--liquid--vapor dissolution of individual tin(IV) oxide
nanowires. ACS Nano. 2014; 8: 5441-5448.
Abstracts
Poster: Edwards DN, Salmeron KE, Lukins DL, Trout AL, Fraser JF and Bix GJ: Inhibition
of α5β1 integrin with the small peptide ATN-161 reduces inflammation, stabilizes the bloodbrain barrier, and is neuroprotective after experimental ischemic stroke. International Stroke
Conference 2019, Honolulu, HI. February 7. 2019.

Oral Abstract: Edwards DN, Salmeron KE, Lukins DL, Fraser JF and Bix GJ. ATN161 stabilizes the blood-brain barrier and is neuroprotective after experimental
ischemic stroke through inhibition of integrin α5β1. International Symposium of
Neuroprotection and Neurorepair, Dresden, Germany. October 10, 2018.
158

Poster: Edwards DN, Salmeron KE, Lukins DL, Fraser JF and Bix GJ. Inhibition Of
Integrin α5β1 with the Small Peptide ATN-161 Reduces Infarct Volume And Improves
Functional Recovery Through Reduction Of Blood-brain Barrier Permeability. CCTS
Spring Conference, Lexington, KY. April 13, 2018.
Moderated Poster: Edwards DN, Salmeron KE, Fraser JF and Bix GJ. Inhibition of
Integrin α5β1 With The Small Peptide Atn-161 Reduces Infarct Volume And Improves
Functional Recovery Through Reduction Of Blood-brain Barrier Permeability.
International Stroke Conference, Los Angeles, CA. January 24, 2018.
Oral Abstract: Edwards DN, Salmeron KE, Fraser JF and Bix GJ. Inhibition of

α5β1 with the clinically validated small peptide ATN-161 is neuroprotective
and functionally restorative in experimental stroke. APSA-ASCEPT Joint
Scientific Meeting 2017, Brisbane, Australia. December 6, 2017.
Oral Abstract: Edwards DN, Salmeron KE, Fraser JF and Bix GJ. ATN-161

stabilizes the blood-brain barrier and is neuroprotective after experimental
ischemic stroke through inhibition of integrin α5β1. Cerebral Vascular
Disease 2017, Melbourne, Australia. November 29, 2017.
Poster: Edwards DN, Kitanno BR, Macrase MI, Fraser JF, McCabe C, and Bix GJ.
Neuroprotective effects of inhibition of α5β1 integrin following experimental stroke:
A dual center pre-clinical study. Association for Clinical and Translational Science
2017, Washington D.C. April 19,2017.
Poster: Edwards DN, Salmeron KE, Fraser JF and Bix GJ. Inhibition of α5β1
integrin with ATN-161 is neuroprotective and stabilizes the blood-brain barrier after
experimental ischemic stroke. Brain 2017, Berlin, Germany. April 2, 2017.
Oral Abstract: Edwards DN, Kitanno BR, Macrase MI, Fraser JF, McCabe C, and
Bix GJ. Neuroprotective effects of inhibition of α5β1 integrin following experimental
stroke: A dual center pre-clinical study. CCTS Spring Conference 2017, Lexington
KY. March 30, 2017.
Oral Abstract: Edwards DN, Kitanno BR, Macrase MI, Fraser JF, McCabe C, and
Bix GJ. Neuroprotective effects of inhibition of α5β1 integrin following experimental
stroke: A dual center pre-clinical study. International Stroke Conference, Houston,
TX. February 22, 2017.
Oral Abstract: Edwards DN, Kitanno BR, Grohs G, Macrase MI, Fraser JF, McCabe
C, and Bix GJ. Neuroprotective effects of inhibition of α5β1 integrin following
experimental stroke: A dual center pre-clinical study. Podium. Clinical Translational
Research Symposium, Lexington, KY. September 23, 2016.

159

Oral Abstract: Edwards DN, Roberts J, de Hoog L, and Bix GJ. Inhibition of strokeelevated endothelial α5β1 integrin stabilizes the blood-brain barrier and is
neuroprotective. European Stoke Organization Conference, Barcelona, Spain. May
10, 2016.
Oral Abstract: Edwards DN, Roberts J, de Hoog L, and Bix GJ. Acute inhibition of
α5β1 integrin protects claudin-5 expression and stabilizes the blood-brain barrier.
Neuroprotection & Neurorepair, Leipzig, Germany. April 20, 2016.
Oral Abstract: Edwards DN, Roberts J, de Hoog L, and Bix GJ. Acute upregulation
of α5β1 Integrin destabilizes the blood-brain barrier after stroke. International Stroke
Conference, Los Angeles, CA. February 17, 2016.
Poster: Edwards DN, Roberts J, de Hoog L, and Bix GJ. Acute upregulation of α5β1
Integrin destabilizes the blood-brain barrier after stroke. Markesbery Symposium,
Lexington KY. November 20, 2015.

160

